Latest

CRH Q3 Revenue Rises 3% as Acquisitions Offset Cost Inflation; $6 Billion Buyback Announced CRH (NYSE: CRH) reported third-quarter 2026

CRH (NYSE: CRH) reported third-quarter 2026 revenue of $11.4 billion, up 3% year over year, supported by pricing, resilient underlying demand and contributions from...

11-01-26

Atlassian Introduces Context Quality Score to Improve AI Performance Across Cloud Products Atlassian (NASDAQ: TEAM) introduced Context Quality Score, a

Atlassian (NASDAQ: TEAM) introduced Context Quality Score, a new metric designed to help organizations assess whether their internal data and knowledge are sufficiently complete,...

11-01-26

General Dynamics Q3 Revenue Rises 13% as Defense Orders Drive Record Backlog General Dynamics (NYSE: GD) reported strong third-quarter 2026

General Dynamics (NYSE: GD) reported strong third-quarter 2026 results, with revenue increasing 12.9% year over year to $14.6 billion and diluted EPS rising 15.7%...

11-01-26

Aon and SAGE Launch AI-Powered Precision Crop Insurance Program Across 15 States Aon (NYSE: AON) and agricultural risk-intelligence company SAGE

Aon (NYSE: AON) and agricultural risk-intelligence company SAGE announced a new precision crop insurance program designed to use field-level data and AI to improve...

11-01-26

Mondelēz Q3 Revenue Rises 2.3% as Volume Growth and Margin Expansion Support Results Mondelēz International (NASDAQ: MDLZ) reported third-quarter 2026

Mondelēz International (NASDAQ: MDLZ) reported third-quarter 2026 net revenue of $10.0 billion, up 2.3% year over year, while organic net revenue increased 2.1%. Volume/mix...

11-01-26

Regeneron Q3 Revenue Jumps 36% as Dupixent, EYLEA HD and Libtayo Drive Growth Regeneron Pharmaceuticals (NASDAQ: REGN) reported a strong

Regeneron Pharmaceuticals (NASDAQ: REGN) reported a strong third quarter of 2026, with revenue rising 36% year over year to $5.1 billion as key products...

11-01-26

Trane Technologies Raises 2026 Revenue Guidance as Orders, Backlog and Sales Growth Accelerate Trane Technologies (NYSE: TT) reported strong third-quarter

Trane Technologies (NYSE: TT) reported strong third-quarter 2026 results, with revenue rising 18% year over year to $6.8 billion and organic revenue increasing 16%....

11-01-26

Palo Alto Networks Urges Shareholders to Reject Tutanota Mini-Tender Offer Palo Alto Networks (NASDAQ: PANW) advised shareholders to reject an

(NASDAQ: PANW) advised shareholders to reject an unsolicited mini-tender offer from Tutanota LLC seeking to purchase up to 250,000 shares of...

11-01-26

Lockheed Martin Expands $25 Million 25Forward Initiative Through 11 New Partnerships Lockheed Martin (NYSE: LMT) expanded its 25Forward initiative through

Lockheed Martin (NYSE: LMT) expanded its 25Forward initiative through new and broadened partnerships with 11 organizations focused on preserving the legacy of Sept. 11,...

11-01-26

Bristol Myers Squibb Raises 2026 Revenue Outlook as Growth Portfolio Sales Increase 12% Bristol Myers Squibb (NYSE: BMY) reported third-quarter

(NYSE: BMY) reported third-quarter 2026 revenue of $13.1 billion, up 7% year over year, supported by continued double-digit growth across its...

11-01-26

Starbucks Q4 Comparable Sales Rise 7.2% as Turnaround Gains Momentum and FY27 Guidance Begins Starbucks (NASDAQ: SBUX) reported stronger fiscal

Starbucks (NASDAQ: SBUX) reported stronger fiscal fourth-quarter 2026 operating trends, with global comparable coffeehouse sales rising 7.2% as both traffic and average ticket improved....

11-01-26

Abbott Launches Pivotal Trial for Cephea Mitral Valve Replacement System Abbott (NYSE: ABT) has initiated the CROWN-MV pivotal trial evaluating

Abbott (NYSE: ABT) has initiated the CROWN-MV pivotal trial evaluating its investigational Cephea Mitral Valve System, a minimally invasive transcatheter replacement therapy for patients...

11-01-26

NYSE:LMTFollow

Track all markets on TradingView - Prices are not updated in real time

Lockheed Martin Expands $25 Million 25Forward Initiative Through 11 New Partnerships

Lockheed Martin (NYSE: LMT) expanded its 25Forward initiative through new and broadened partnerships with 11 organizations focused on preserving the legacy of Sept. 11, supporting veterans and first responders, and strengthening community preparedness.

The five-year program represents a $25 million commitment tied to the 25th anniversary of the Sept. 11 attacks. Lockheed Martin said the initiative is designed to preserve historical stories, support survivors and military families, and expand education, volunteerism and disaster-readiness efforts.

Partner organizations include 9/11 Day, the FDNY Foundation, Friends of Flight 93 National Memorial, Gary Sinise Foundation, Pentagon Memorial Fund, Scholarship America, Soldiers’ Angels and Team Rubicon, among others.

Lockheed Martin initially launched 25Forward in September with a $10 million contribution to the Pentagon Memorial Visitor Education Center. The broader initiative will continue over the next five years.

The announcement is primarily a corporate social responsibility development rather than a direct financial catalyst, but it reinforces Lockheed Martin’s long-term engagement with military, veteran and national-service communities closely aligned with its defense business and brand positioning.

💬 🔗

Global Finance News 11-01-26

Lockheed Martin Jumps 6% as Q3 Sales, Earnings and Record Backlog Drive Guidance Raise

Lockheed Martin (NYSE: LMT) shares rose about 6% after the defense contractor reported stronger third-quarter 2026 sales and earnings, record backlog and another increase to its full-year financial outlook.

Third-quarter sales increased 11% year over year to $20.7 billion, while net earnings rose 14% to $1.85 billion. Diluted EPS climbed to $7.97 from $6.95 a year earlier. All four business segments posted revenue growth during the quarter.

Backlog surged 27% from the second quarter to a record $292.0 billion, including $52.5 billion tied to the multi-year PAC-3 Missile Segment Enhancement contract. The backlog expansion materially improves revenue visibility and highlights sustained demand for missile defense and other major defense programs.

Missiles and Fire Control was particularly strong, with revenue rising 24% to $4.50 billion and operating profit increasing 24% to $631 million. Growth was driven by production ramps across PAC-3, THAAD, GMLRS and Precision Strike Missile programs.

Aeronautics revenue increased 13% to $8.21 billion, mainly due to higher F-35 production and sustainment activity, while Rotary and Mission Systems and Space also posted revenue growth.

Lockheed raised its 2026 sales outlook to approximately $80 billion-$82 billion from $79.75 billion-$81.75 billion. EPS guidance increased to about $30.35-$30.75, while free cash flow guidance was lifted substantially to $7.8 billion-$8.0 billion from $7.0 billion-$7.2 billion.

Free cash flow for the quarter was $3.0 billion, down from $3.35 billion a year earlier, largely because the prior-year period benefited from higher customer receipts.

The 6% gain appears to reflect the combination of double-digit earnings growth, accelerating missile-defense production, a record $292 billion backlog and the second consecutive quarterly increase in full-year guidance.

💬 🔗

European Investor 10-22-26

Lockheed Martin Wins Philippine Air Force Contract for S-70i Black Hawk Training Systems

Lockheed Martin signed a Direct Commercial Sale contract with the Philippine Department of National Defense to provide S-70i Black Hawk training systems and related services to the Philippine Air Force.

The contract includes a full-flight simulator, a virtual maintenance trainer and associated courseware, giving the Philippine Air Force the ability to train pilots and maintainers domestically as its Black Hawk fleet expands.

The full-flight simulator uses a digital twin of the S-70i to replicate the aircraft’s flight characteristics, while the virtual maintenance trainer provides immersive, physics-based simulations of systems ranging from hydraulics to avionics.

The agreement also includes sustainment and spare-parts support through 2032. Philippine pilots will continue training at Sikorsky’s U.S.-based training academy while local training capability is established.

For Lockheed Martin, the deal marks the first order for its S-70i Black Hawk training devices and expands its simulation and sustainment business in the Asia-Pacific region. It also strengthens the company’s relationship with the Philippine Air Force as the country continues broader defense modernization efforts.

💬 🔗

European Investor 10-08-26

Lockheed Martin Completes First Flight of Morocco’s First F-16 Block 72

Lockheed Martin (NYSE: LMT) announced the successful first flight of the Royal Moroccan Air Force’s first F-16 Block 72 aircraft, marking a major milestone ahead of initial delivery.

The F-16 Block 72 is the latest and most advanced version of the Fighting Falcon, featuring upgraded avionics, advanced sensors, improved mission systems and enhanced safety and reliability capabilities.

Lockheed Martin said the aircraft will now continue through flight testing as Morocco advances its F-16 modernization program. The company described the program as an important step in strengthening the country’s future airpower and regional defense capabilities.

The milestone also builds on a defense relationship between Lockheed Martin and Morocco that spans more than five decades. Morocco currently operates Lockheed Martin platforms including F-16s, C-130s, radar systems and Black Hawks, and is also set to receive HIMARS systems.

Lockheed is also expanding its industrial footprint in Morocco through initiatives including a new maintenance, repair and overhaul facility in Benslimane, which is initially designed to support C-130 aircraft and could later expand to the F-16 platform.

💬 🔗

The Investor 10-06-26

Boeing (NYSE: BA) has received an approximately $14.7 billion contract action from Lockheed Martin (NYSE: LMT) to expand production and deliver PAC-3 Missile Segment Enhancement seekers.

The seven-year framework is designed to triple Boeing’s PAC-3 MSE seeker production. The seekers are used in advanced Patriot interceptors to identify, track and engage threats including aircraft, ballistic missiles, cruise missiles and hypersonic weapons.

Boeing has already invested in expanding its PAC-3 seeker manufacturing capacity, modernizing facilities and strengthening its supplier network. The production ramp-up is also expected to create hundreds of direct and indirect jobs in the Huntsville, Alabama, area.

The contract supports a broader U.S. effort to accelerate production and delivery of key defense systems.

💬 🔗

Global Finance News 10-06-26

Lockheed Martin and U.S. Army Reach Flexible Black Hawk Production Agreement

Lockheed Martin’s Sikorsky unit and the U.S. Army reached a new production agreement for Black Hawk helicopters designed to accelerate deliveries for both U.S. and allied customers.

The initial agreement covers 16 aircraft for the U.S. Army, with the total expected to increase by more than 100 helicopters in coming years as requirements develop and foreign military sales cases mature. Deliveries are scheduled to begin in 2028.

The structure gives the Army flexibility to add aircraft as demand emerges while maintaining uninterrupted production across Sikorsky and its 230-supplier industrial base spanning 43 states.

Funding for the first 16 helicopters will come from fiscal 2025 and 2026 congressional appropriations as well as proceeds from the Black Hawk Exchange and Sales Transaction program, which allows the Army to reinvest revenue from divested older aircraft into new purchases.

Sikorsky is also continuing to modernize the Black Hawk platform with upgrades including more powerful engines, increased payload capacity, longer range, launched effects, autonomy and a Modular Open Systems Approach digital backbone.

More than 5,000 Black Hawk helicopters have been delivered to over 36 allied nations, accumulating more than 15 million flight hours. The agreement is intended to sustain the production base while giving the Army and international partners a faster path to new aircraft.

💬 🔗

The Investor 09-30-26

Avio USA Breaks Ground on Virginia Solid Rocket Motor Facility to Expand U.S. Defense Capacity

Avio USA has broken ground on its first U.S. manufacturing facility, a roughly 900,000-square-foot solid rocket motor plant in Hurt, Virginia, aimed at expanding domestic missile and munitions production capacity.

The facility is expected to produce thousands of solid rocket motors annually for U.S. tactical missile programs and create around 1,500 technical jobs in Southern Virginia. Construction is expected to be completed by late 2028, with production beginning in early 2029.

Avio USA, a subsidiary of Italy-based Avio, plans to operate as an independent supplier to multiple U.S. defense customers and prime contractors. The company said the facility will add capacity, increase competition and improve resilience in the U.S. solid rocket motor supply chain.

The plant is being developed to support requirements across the U.S. defense industry, including programs for Lockheed Martin and Raytheon. Lockheed Martin said the project should help diversify and strengthen the supply base for solid rocket motors that are critical to missile production.

HITT Contracting is serving as general contractor for the project.

The investment reflects the broader effort by defense contractors and suppliers to expand U.S. manufacturing capacity for missiles and energetics, particularly in areas where limited supplier capacity has become a constraint on production growth.

💬 🔗

WS Investor 09-29-26

Lockheed Martin and GM Defense Accelerate PAC-3 MSE Component Production

Lockheed Martin said GM Defense delivered the first mission-critical components for the PAC-3 Missile Segment Enhancement interceptor just 22 days after the companies signed a formal contract, highlighting efforts to accelerate U.S. munitions production.

The agreement was signed on August 6, with the first batch of PAC-3 MSE housing components delivered on August 28. Lockheed Martin said components of this type can traditionally take months or even years to produce, making the rapid turnaround a notable example of applying commercial manufacturing practices to defense production.

GM Defense used its advanced casting and machining capabilities to meet military specifications, while Lockheed Martin said the partnership demonstrates how commercial manufacturing capacity can help expand the defense industrial base and improve missile production speed.

The effort comes as Lockheed Martin invests between $8 billion and $9 billion to expand munitions production across the U.S. The company said planned expansions will increase its production and warehousing space for munitions by nearly 50% and support programs including PAC-3 MSE, THAAD and Precision Strike Missile.

Lockheed Martin and GM Defense said they plan to expand the partnership further, applying commercial manufacturing practices across additional munitions and future defense programs.

💬 🔗

The Investor 09-17-26

Lockheed Martin Demonstrates Networked Legion Sensor System on F-16s

Lockheed Martin (NYSE: LMT) successfully demonstrated a new pod-to-pod data link for its Legion sensor system during F-16 flight tests with the U.S. Air National Guard and Air Force Reserve Test Center.

Two F-16s equipped with Legion pods connected through L3Harris’ HiveLink data link and shared sensor information in flight, improving target-track accuracy. The capability allows pilots to establish near-instantaneous engagement solutions against multiple airborne targets, particularly in contested or radar-denied environments.

Legion is a passive infrared search-and-track system, meaning aircraft can detect and track airborne targets without relying on active radar emissions. Connecting multiple Legion-equipped aircraft allows their sensor data to be combined, providing more accurate range and positioning information while reducing pilot workload and shortening engagement timelines.

Lockheed Martin is continuing F-16 flight testing and plans further development involving software-defined radios, multi-waveform gateways and manned-unmanned teaming. Legion is already in production for the U.S. Air Force and can operate across F-15 and F-16 platforms, with its open architecture supporting integration into additional fighter and unmanned aircraft.

💬 🔗

WS Investor 09-16-26

IBM and Lockheed Martin Launch Swiss Quantum Innovation Hub at ETH Zurich

IBM and Lockheed Martin have established a new quantum innovation hub at ETH Zurich that will host Switzerland’s first IBM Quantum System Two, expanding access to advanced quantum computing for Swiss universities, industries and startups.

The system will be installed at the Swiss National Supercomputing Centre in Lugano and operated by IBM. It will use IBM’s Quantum Nighthawk processor, while ETH Zurich will provide expertise and resources to support research, workforce development and new industrial applications. Deployment is expected by the end of 2026.

Organizations participating in the hub will initially gain access to IBM’s existing quantum computers through the cloud before receiving access to the dedicated Swiss system. Potential applications include chemistry, materials science, optimization and financial services.

The initiative also expands the existing IBM-Lockheed Martin partnership. The companies plan joint research projects exploring quantum sensing for navigation and the use of advanced technologies to improve additive manufacturing of metallic alloys, with potential applications in aerospace and defense.

💬 🔗

The Investor 09-10-26

Load More

09-05-26European Investor

01-09-26WS Investor

12-19-25Global Finance News

10-20-25WS Investor

09-15-25WS News

NASDAQ:MCHPFollow

Track all markets on TradingView - Prices are not updated in real time

Microchip Expands PolarFire FPGA Platform With EtherCAT and TSN for Industrial AI and Robotics

Microchip Technology (NASDAQ: MCHP) expanded its PolarFire FPGA and SoC platform with EtherCAT and Time-Sensitive Networking capabilities, targeting industrial automation, robotics and intelligent edge applications that require deterministic real-time communications.

The new industrial edge networking stack combines PolarFire hardware with networking IP, development tools and reference designs. Beckhoff EtherCAT IP is now compatible with PolarFire FPGA and SoC devices, while Microchip’s TSN IP is supported on PolarFire FPGA SoCs.

The platform supports EtherCAT connectivity at 10/100/1000 Mbps and deterministic 1 Gbps Ethernet using IEEE 802.1 TSN standards. Microchip said the combination is designed to help developers build scalable industrial networks with predictable latency and interoperability across connected devices.

PolarFire’s architecture also emphasizes power efficiency and security, including instant-on operation, secure boot and anti-tamper features. The FPGA fabric allows developers to combine real-time networking with application-specific processing and customization.

Target markets include motion control, factory automation, industrial robotics, embedded vision, autonomous mobile robots, automotive systems, smart infrastructure, aerospace and defense.

The announcement strengthens Microchip’s industrial-edge offering as manufacturers increasingly integrate AI, machine learning and real-time networking closer to machines and production systems. While the release does not provide financial guidance or expected revenue contribution, the expanded PolarFire stack broadens Microchip’s addressable opportunities in industrial automation and edge computing.

💬 🔗

Global Finance News 11-01-26

Microchip Launches New Touch Controllers for Display-Free Human Machine Interfaces

Microchip Technology introduced the MTCH3380P and MTCH3240P, its first turnkey capacitive-touch controllers to use parallel sensing for buttons, sliders and wheels.

The new devices are designed for display-free human machine interfaces used in appliances, industrial equipment and outdoor systems, where large numbers of touch sensors can otherwise slow response times and reduce signal quality.

Both controllers use 12 on-chip analog-to-digital converters operating in parallel. The MTCH3380P supports up to 38 sensors in self-capacitance mode and 64 in mutual-capacitance mode, while the MTCH3240P supports up to 24 and 32 sensors, respectively.

Microchip said the design improves acquisition speed, signal-to-noise ratio and touch reliability, including through thick cover materials and when users are wearing gloves. Target applications include ovens, cooktops, refrigerators, washing machines, EV chargers, parking meters and kiosks.

The devices also support customer-driven IEC 60730 Class B functional safety certification and operation at temperatures up to 105°C.

Pricing starts at $1.06 for the MTCH3380P and $0.80 for the MTCH3240P in 10,000-unit quantities, positioning the products as relatively low-cost components for more advanced capacitive-touch interfaces.

💬 🔗

European Investor 10-08-26

Microchip Expands Single Pair Ethernet Portfolio for Automotive and Industrial Edge Networks

Microchip Technology has expanded its 10BASE-T1S portfolio with new transceivers and integrated endpoint devices designed to simplify Ethernet connectivity at the network edge.

The new lineup includes the LAN8679 and LAN8680 transceivers, as well as the LAN8660X/1X/2X endpoint family. The products are aimed at automotive zonal architectures, industrial automation, robotics and other applications where designers are trying to reduce wiring, simplify network architecture and connect more edge devices directly to Ethernet.

The LAN8679 uses a standardized Open Alliance 3-Pin interface in a compact package, while the LAN8680 adds system-level functions including power management, wake and sleep control and watchdog supervision. Both are designed to support demanding automotive and industrial environments and are being developed with AEC-Q100 and ISO 26262 requirements in mind.

Microchip’s LAN8660X/1X/2X family goes a step further by integrating the transceiver into a single-chip Remote Control Protocol solution, reducing the need for separate PHY components in applications such as lighting, control systems and audio.

A key advantage of 10BASE-T1S is its multidrop architecture. Multiple nodes, typically eight or more, can share a single bus line, potentially reducing wiring weight, system cost and gateway requirements.

The launch strengthens Microchip’s position in the shift toward all-Ethernet architectures, particularly in vehicles and industrial systems where more sensors and actuators are being connected directly to distributed edge networks.

💬 🔗

WS Investor 09-29-26

Microchip Launches New 65V Digital Power Monitors for 48V AI, Automotive and Industrial Systems

Microchip Technology (NASDAQ: MCHP) introduced its new PAC1761 and PAC1861 families of 65V energy-aware digital power monitors, targeting growing demand for 48V power architectures across AI data centers, automotive, networking and industrial applications.

The new devices are designed to monitor not only real-time voltage, current and power, but also accumulated energy consumption over time. Microchip said the monitors provide up to 65V measurement capability and 75V transient spike protection, helping designers improve efficiency, reliability and system resilience in higher-power 48V environments.

Key features include programmable alerts for voltage, current and power excursions, step-limit detection for sudden load changes, and configurable accumulated-energy thresholds. The products are available in 12-bit PAC1761 and 16-bit PAC1861 versions, with pin-compatible package options intended to reduce redesign and qualification requirements.

The PAC1761 and PAC1861 families are available now, with pricing starting at $0.56 per unit in 10,000-unit quantities. The products are aimed at applications including AI/data centers, servers, telecom infrastructure, automotive systems and 48V power distribution.

💬 🔗

WS Investor 09-24-26

Microchip Technology Completes Hailo Acquisition to Expand Edge AI Portfolio

Microchip Technology said it completed its acquisition of Hailo, adding AI accelerators, vision processors, robotics processors and related software to its semiconductor portfolio. Financial terms were not disclosed, and Microchip said the transaction is not expected to have a material impact on its financial results.

The acquisition strengthens Microchip’s position in Edge AI, machine vision, robotics and Physical AI. By combining Hailo’s AI and vision technologies with Microchip’s embedded processing, connectivity, security, analog, FPGA and power products, the company aims to offer more complete platforms for intelligent systems at the edge.

Hailo’s portfolio supports computer vision, transformer-based models, multimodal workloads and advanced video analytics. Microchip said the combined offering could address applications ranging from low-power smart cameras to autonomous machines and high-performance robotics.

Hailo also brings more than 100 customers and a developer community of over 10,000 users. Microchip plans to continue supporting Hailo’s existing products and software environment while investing in future AI acceleration and vision-processing technologies.

The deal reflects Microchip’s broader push to capture growing demand for AI inference outside centralized data centers, particularly in industrial, automotive, robotics and other embedded applications.

💬 🔗

European Investor 09-21-26

Microchip Technology Expands Edge AI Reach With AnalogAI Partnership

Microchip Technology (NASDAQ: MCHP) said AnalogAI has selected memBrain SAGE technology from its Silicon Storage Technology subsidiary for AnalogAI’s first real-world edge AI processors. The processors are designed to train and run AI models directly on devices rather than relying on cloud infrastructure.

AnalogAI will use Microchip’s analog compute-in-memory technology to target AI performance at or below one watt, enabling ultra-low-power applications including humanoid robots, drones and vehicles that can adapt to changing environments in real time.

The memBrain SAGE platform integrates computation and memory functions and is already deployed using 40-nanometer and 28-nanometer manufacturing processes, while Microchip is developing a 22-nanometer version. AnalogAI said it selected the technology following an industry-wide evaluation, citing its combination of power efficiency, performance and faster development time.

The deal expands Microchip’s exposure to the growing edge-AI market, where robotics and autonomous systems increasingly require AI inference and adaptation directly on devices with tight power constraints.

💬 🔗

The Investor 09-15-26

Microchip Launches 1.2V Clock Buffers for AI, FPGA and SoC Applications

Microchip Technology (NASDAQ: MCHP) introduced its new SY757xx family of 1.2V-output LVCMOS clock buffers, targeting growing demand from high-performance FPGAs, SoCs, AI accelerators and next-generation CPUs.

The new clock buffers are designed to connect advanced processors requiring low-voltage clock signals with components operating at higher voltages. The devices support voltage translation across a 1.2V-to-3.3V input range and frequencies from 0 Hz to 250 MHz, providing a single-chip alternative to discrete components and voltage-divider designs.

Microchip said the SY757xx family delivers additive jitter as low as 26 femtoseconds, helping preserve signal integrity and clock accuracy in applications where precise timing is critical. Potential uses include AI and machine-learning acceleration, industrial control, embedded vision, networking, communications and real-time computing.

Three products in the family are already in volume production, while another eight are sampling in limited quantities. The production devices offer configurations with two or four LVCMOS outputs and are available in compact VDFN and TDFN packages.

Pricing for the SY75707TWL-TR, SY75712TWL-TR and SY75714TWL-TR ranges from $0.50 to $0.83 per unit in quantities of 10,000.

The launch expands Microchip’s timing portfolio as increasingly advanced semiconductor architectures move toward lower operating voltages. By integrating voltage translation and low-jitter clock distribution into a single device, Microchip aims to reduce component counts, lower bill-of-materials costs and simplify board designs for next-generation computing systems.

💬 🔗

The Investor 09-08-26

Microchip and Marelli Launch Open-Standard Display Connectivity Solution for Software-Defined Vehicles

Microchip Technology (NASDAQ: MCHP) and automotive technology supplier Marelli have introduced a new open-standard display connectivity solution designed for the rapidly developing software-defined vehicle market.

The joint solution allows graphics and video generated by a vehicle’s centralized computer to be streamed directly to automotive displays using ASA Motion Link, or ASA-ML. The technology is intended to simplify vehicle display architectures, reduce system costs and give automakers greater flexibility when selecting component suppliers.

The system uses Microchip’s VS7000 ASA-ML chipset to process and transmit video and graphics over a standardized high-speed connection. Marelli provides the display-side integration, enabling standardized streams carrying camera feeds, navigation maps, infotainment graphics and vehicle-control interfaces to be decoded directly at the display.

A key aspect of the technology is its use of an open standard rather than a proprietary automotive video interface. ASA-ML was developed by the Automotive SerDes Alliance, whose members include automakers, Tier 1 suppliers and semiconductor companies. Microchip is a founding member of the alliance. The standard is designed to allow components from different technology suppliers to operate together, potentially reducing vendor dependence for automakers.

The solution supports data rates of up to 16 Gbps, along with link-layer authentication and encryption, lossless data transmission and resistance to electromagnetic interference. It also provides a pathway toward increasingly Ethernet-centric vehicle architectures.

For Microchip, the collaboration expands its automotive connectivity opportunity as vehicle manufacturers increasingly shift toward centralized computing and software-defined architectures. Rather than using separate computing resources for individual displays and functions, next-generation vehicles are moving toward powerful central computers connected to distributed displays, cameras and other endpoints. Microchip’s ASA-ML technology positions the company to provide part of the high-speed connectivity infrastructure required by that transition.

💬 🔗

European Investor 09-03-26

# Microchip Technology Expands Space Semiconductor Portfolio With New Atomic Clock

Microchip Technology (NASDAQ: MCHP) announced the launch of its Space CSAC-SA65, a radiation-tolerant Chip Scale Atomic Clock designed for satellites and other space systems.

The new device combines atomic-clock accuracy with low power consumption and a compact design. It offers radiation tolerance of at least 30 kRad, operates across temperatures from -40°C to +80°C and consumes less than 120 mW.

## Targeting Growing Satellite Demand

The CSAC-SA65 is designed particularly for Low Earth Orbit missions, including satellite communications, navigation, Earth imaging and satellite cross-linking. Its built-in synchronization capabilities allow spacecraft to maintain precise timing even when external references such as GNSS signals are unavailable.

Microchip said the product uses radiation-tolerant commercial components, potentially providing lower costs and shorter lead times than traditional radiation-hardened space timing systems.

The launch strengthens Microchip's position in aerospace and defense semiconductors while giving the company additional exposure to growing demand for smaller, lower-cost satellite platforms and New Space applications.

💬 🔗

European Investor 08-13-26

Microchip Advances Edge AI Push With New NVIDIA-Compatible PolarFire Sensor Bridge

Microchip Technology (NASDAQ: MCHP) announced the release of its second-generation PolarFire FPGA Ethernet Sensor Bridge, expanding its hardware offering for NVIDIA-powered edge AI applications.

The new Rev 2.0 platform is 60% smaller than its predecessor, supports twice as many cameras and uses 10Gb Ethernet connectivity. It is designed to work with NVIDIA Holoscan Sensor Bridge technology and edge computing platforms including NVIDIA Jetson and IGX.

The platform supports up to four cameras and enables real-time multi-sensor processing with end-to-end latency measurement. Microchip said the architecture can reduce power consumption, system costs and integration complexity for applications including humanoid robotics, industrial automation and AI-enabled medical systems.

The launch strengthens Microchip's exposure to the growing edge AI ecosystem, where increasingly complex AI workloads require high-speed connections between cameras, sensors and local computing hardware.

For Microchip, the NVIDIA-compatible platform also provides another potential growth avenue for its PolarFire FPGA portfolio as AI adoption expands beyond data centers into robotics, industrial equipment and other physical AI applications.

💬 🔗

The Investor 08-11-26

Load More

01-17-26WS News

NYSE:AONFollow

Track all markets on TradingView - Prices are not updated in real time

Aon and SAGE Launch AI-Powered Precision Crop Insurance Program Across 15 States

Aon (NYSE: AON) and agricultural risk-intelligence company SAGE announced a new precision crop insurance program designed to use field-level data and AI to improve risk assessment and insurance pricing for U.S. corn and soybean growers.

The program, developed with specialty agricultural insurer AgriCap, is expected to be available across 15 states for the 2027 crop year. It is designed to complement federal crop insurance by matching coverage more closely to the value and risk characteristics of individual fields rather than relying primarily on county-level averages.

The approach combines SAGE’s AI models, which analyze soil, water, weather and farm-management data, with Aon’s insurance analytics and risk-capital capabilities. The companies said the goal is to convert field-level resilience and risk signals into information that can be used directly in insurance underwriting and capital allocation.

A four-county pilot is already underway in Michigan through the Resilience in Agricultural Lending and Insurance Coalition. The pilot covers more than one million agricultural acres, representing about 12% of the state’s farmland.

The program addresses a limitation in traditional crop insurance, where premiums may not fully capture differences in risk between individual farms or fields. By using more granular data, Aon and SAGE aim to create insurance structures that better reward growers investing in resilience while also helping insurers price risk more precisely.

The initiative expands Aon’s use of AI and advanced analytics within agricultural insurance and could create a scalable model for other crops and regions if the 2027 rollout proves successful.

💬 🔗

Global Finance News 11-01-26

Aon Rises 3.9% as Organic Growth, Margin Expansion and EPS Gains Drive Strong Q3

Aon (NYSE: AON) shares rose about 3.9% after the company reported solid third-quarter 2026 organic growth, higher adjusted earnings and improving profitability across its major businesses.

Revenue increased 3% year over year to $4.1 billion, while organic revenue grew 6%. Growth was broad-based, including 7% in Commercial Risk, 7% in Reinsurance, 6% in Health and 4% in Wealth.

Adjusted operating income increased 5% to $1.11 billion, while adjusted operating margin expanded 70 basis points to 27.0%. Adjusted EPS rose 10% to $3.36, compared with $3.05 a year earlier.

Cash generation remained solid, with third-quarter operating cash flow of $1.19 billion and free cash flow of $1.10 billion. For the first nine months, free cash flow increased 3% to $1.94 billion.

Aon also expects its acquisition of USI to close during the fourth quarter. Following the transaction, management plans to prioritize debt reduction, targeting leverage of approximately 2.8x-3.0x within about two years.

The 3.9% gain appears to reflect strong underlying organic growth, margin expansion and double-digit adjusted EPS growth, alongside management’s confidence in maintaining momentum through the remainder of 2026.

💬 🔗

WS Investor 10-28-26

Aon Selects Vanguard to Expand $7.7 Billion Pooled Employer Plan

Aon (NYSE: AON) has selected Vanguard as recordkeeper and trustee for the Aon Pooled Employer Plan, while also planning to expand the availability of Vanguard investment options within the retirement platform.

The Aon PEP has grown to approximately $7.7 billion in assets since launching in 2021 and now serves more than 160 employers and over 103,000 participants.

Aon said the changes are designed to improve participant outcomes, simplify administration and strengthen the plan’s long-term value. Vanguard will provide recordkeeping, trustee services, investment options and participant support resources.

The expanded offering is expected to include additional target-date and core index strategies, financial wellness resources and institutional-scale pricing benefits.

Aon said employers will continue to retain control over key plan design decisions, including matching contributions, eligibility requirements and vesting schedules.

The move reflects growing demand for pooled employer plans as companies seek to reduce administrative complexity while offering more competitive retirement benefits.

💬 🔗

The Investor 10-06-26

Aon’s NFP Acquires Moores Insurance to Expand Minnesota Presence

NFP, an Aon company (NYSE: AON), has acquired Minneapolis-based Moores Insurance Management, expanding its property and casualty insurance operations in Minnesota. Financial terms of the transaction were not disclosed.

Founded in 1987, Moores provides risk-management and insurance services to high-net-worth individuals and commercial clients across 43 U.S. states. The acquisition strengthens NFP’s capabilities in both commercial P&C insurance and personal risk services.

Moores CEO Mark Moores will join NFP as senior vice president of Commercial P&C, while President Jack Moores will become senior vice president of Personal Lines. The existing team will gain access to NFP’s broader insurance, employee benefits, wealth management and retirement advisory capabilities.

For Aon, the transaction represents another expansion of NFP’s U.S. distribution network, strengthening its presence in the Twin Cities market and increasing its reach among high-net-worth individuals and business owners.

💬 🔗

The Investor 09-15-26

Aon to Acquire USI for $17 Billion, Expanding U.S. Middle-Market Insurance Business

Aon (NYSE: AON) announced Monday that it has agreed to acquire insurance brokerage firm USI from KKR and other shareholders for $17 billion, significantly expanding its presence in the U.S. middle-market insurance sector.

USI is the tenth-largest U.S. insurance broker, generating approximately $3 billion in annual revenue with more than 10,500 employees across nearly 200 offices. The company provides property and casualty insurance, employee benefits, personal risk and retirement solutions.

The acquisition builds on Aon's $13.4 billion purchase of NFP in 2024 and will substantially increase its exposure to the more than $40 billion U.S. middle-market segment. Aon will also gain greater access to the fast-growing Excess & Surplus insurance market, which accounts for about 26% of U.S. commercial property and casualty premiums.

Aon expects approximately $395 million in annual run-rate adjusted EBITDA benefits from revenue and cost synergies across its combined middle-market platform. The transaction is expected to become accretive to adjusted EPS beginning in 2028.

The $17 billion purchase will primarily be financed with new debt. As Aon prioritizes deleveraging following the transaction, the company said it does not expect to repurchase shares in the near term.

Following completion, USI Chairman and CEO Mike Sicard will become President of Aon and global CEO of its Middle Market business. The transaction is expected to close in the fourth quarter of 2026, subject to regulatory approvals.

The deal represents a major expansion of Aon's U.S. insurance brokerage operations, combining USI, NFP and Aon's existing businesses into a much larger middle-market platform while expanding its data and AI-enabled insurance capabilities.

💬 🔗

The Investor 08-31-26

Aon Expands Cannabis Insurance Capabilities With Frontier Risk Acquisition

Aon (NYSE: AON) is expanding its presence in specialized insurance markets through NFP’s acquisition of Frontier Risk Group’s retail cannabis insurance business.

The deal adds Frontier Risk’s cannabis-sector insurance and risk management expertise to NFP, strengthening its capabilities in a market characterized by complex and rapidly changing regulation. Financial terms of the transaction were not disclosed.

Frontier Risk provides insurance solutions and risk advisory services for cannabis companies and other regulated-product businesses. As part of the transaction, senior vice president Eric Schneider will join NFP and report to the company’s Healthcare and Life Sciences practice leadership.

The acquisition also complements NFP’s existing life sciences business, giving the company additional expertise in serving clients operating in highly regulated industries.

For Aon, the transaction represents another targeted expansion of its specialty insurance capabilities through NFP. The combination is expected to provide cannabis-sector clients with broader insurance resources while retaining Frontier Risk’s industry-specific expertise.

Following the transaction, Frontier Risk will focus on expanding Strata Specialty, its multi-program manager serving specialized and emerging risk categories.

💬 🔗

The Investor 08-11-26

Aon Stock Falls 1.3% Despite Strong Organic Growth as Lower GAAP EPS Weighs on Investors

Aon (NYSE: AON) shares fell 1.3% on Wednesday despite reporting another quarter of solid organic growth, expanding margins, and reaffirming its full-year outlook, as investors focused on lower GAAP earnings and softer cash flow in the quarter.

The insurance brokerage and professional services company reported second-quarter revenue of $4.25 billion, up 2% year over year, while organic revenue grew a healthy 5%. Operating income increased 7%, with operating margin expanding 80 basis points to 21.5%. Adjusted operating margin also improved 70 basis points to 28.9%, reflecting continued execution of the company's Aon United strategy.

Adjusted EPS rose 9% to $3.81, supported by higher operating profit and continued share repurchases. However, GAAP diluted EPS declined 3% to $2.58, primarily reflecting a higher effective tax rate and unfavorable non-operating items. Quarterly operating cash flow and free cash flow also declined from the prior year, although first-half cash generation remained positive.

Underlying business trends remained resilient. Commercial Risk Solutions, Reinsurance Solutions, Health Solutions, and Wealth Solutions each delivered 5% organic growth, driven by new business wins and strong client retention. The company also returned $775 million to shareholders during the quarter through dividends and share repurchases, while maintaining a strong balance sheet.

Management reaffirmed its full-year 2026 outlook, continuing to expect mid-single-digit or better organic revenue growth, 70 to 80 basis points of adjusted operating margin expansion, strong adjusted EPS growth, and double-digit free cash flow growth. The company also highlighted expanding use of AI-powered analytics and capital solutions to deepen client relationships and support long-term growth.

Despite the positive operational performance, the sharp decline in Aon shares suggests investors were looking for stronger headline results after the stock's recent performance. The combination of lower GAAP EPS, weaker quarterly cash flow, and an outlook that was reaffirmed rather than raised appears to have prompted profit-taking, even as the company's underlying fundamentals and long-term growth strategy remain intact.

💬 🔗

The Investor 07-29-26

Aon (AON) Stock Gains After JPMorgan Raises Price Target

Aon (NYSE: AON) shares climbed about 3% on Monday after JPMorgan raised its price target on the global insurance brokerage and professional services firm to $412 from $396 while maintaining its "Overweight" rating.

The higher price target reflects JPMorgan's continued confidence in Aon's long-term earnings growth, supported by resilient demand for insurance brokerage, risk management, and human capital consulting services. The firm's Overweight rating indicates it expects Aon to outperform the broader market.

Aon has continued to benefit from favorable insurance pricing, recurring fee-based revenue, and steady demand from corporate clients seeking risk advisory and employee benefits solutions. The company has also remained focused on expanding margins through operational efficiencies and technology investments.

The positive analyst action comes as investors remain constructive on insurance brokers, whose business models have proven relatively resilient amid economic uncertainty. Stable cash flows, strong client retention, and consistent capital returns have made the sector attractive to investors seeking defensive growth opportunities.

Monday's rally suggests investors welcomed the higher valuation target and JPMorgan's continued bullish stance. Attention will now turn to Aon's upcoming quarterly earnings, where investors will look for updates on organic revenue growth, margin expansion, and management's outlook for the remainder of the year.

💬 🔗

Global Finance News 07-14-26

Aon Shares Jump 3.7% After Strong Q1 Earnings and Cash Flow Surge

Shares of Aon plc climbed 3.7% to $322.97 today, as investors reacted positively to the company’s first-quarter 2026 earnings report, which highlighted robust profit growth, expanding margins, and a sharp increase in cash generation.

The company reported total revenue of $5.0 billion, up 6% year-over-year, with organic revenue growth of 5%. Growth was primarily driven by strong performance in its Risk Capital segment, reflecting continued demand for risk advisory and insurance solutions.

Profitability significantly outpaced revenue growth. Operating income rose 17% to $1.7 billion, while adjusted operating income increased 8% to $2.0 billion. Operating margin expanded to 34.1%, up from 30.9% a year earlier, signaling improved operational efficiency and cost discipline.

Earnings growth was particularly strong, with diluted EPS rising 27% to $5.63 and adjusted EPS increasing 14% to $6.48. The earnings expansion was further supported by favorable currency effects and ongoing share repurchases.

Cash flow performance stood out as a key highlight. Operating cash flow surged 207% to $430 million, while free cash flow jumped 332% to $363 million, reflecting both higher earnings and improved working capital dynamics. The company returned $662 million to shareholders through dividends and buybacks during the quarter, and also announced a 10% increase in its quarterly dividend.

CEO Greg Case emphasized continued execution of the firm’s “Aon United” strategy and 3x3 Plan, noting that rising global risk complexity is driving demand for integrated, data-driven solutions.

Looking ahead, Aon reaffirmed its full-year 2026 outlook, expecting mid-single-digit or higher organic revenue growth, margin expansion of 70–80 basis points, strong EPS growth, and double-digit free cash flow growth.

Overall, the combination of strong earnings growth, margin expansion, and exceptional cash flow performance appears to have driven investor confidence, pushing the stock higher following the results.

💬 🔗

European Investor 05-01-26

Aon plc announced that its subsidiary NFP has acquired The Hamilton Group, a New Jersey-based insurance broker, to strengthen its property and casualty capabilities in the U.S. Northeast.

The deal enhances NFP’s regional presence and expands its ability to deliver integrated risk management solutions to small and mid-sized businesses in the tri-state area.

💬 🔗

WS Investor 04-14-26

Load More

06-10-25The Investor

NYSE:SNDRFollow

Track all markets on TradingView - Prices are not updated in real time

Norfolk Southern and Schneider Expand Intermodal Partnership Across Eastern U.S.

Norfolk Southern (NYSE: NSC) and Schneider National (NYSE: SNDR) announced a strategic agreement to expand domestic intermodal capacity across the eastern United States, combining Norfolk Southern’s rail network with Schneider’s asset-based intermodal operations.

Under the partnership, Schneider will transition its primary eastern rail provider to Norfolk Southern. The move is intended to broaden Schneider’s access to key markets, improve network flexibility and create additional opportunities to shift freight from truckload transportation to intermodal.

Schneider brings approximately 23,900 chassis, 26,800 containers and access to more than 60 intermodal rail hubs across North America. More than 90% of its domestic dray moves are handled by company drivers, giving the carrier greater control over pickup and delivery operations.

Norfolk Southern, meanwhile, is investing across its 22-state intermodal network, including terminal expansions, gateway capacity, double-stack clearance projects and reliability improvements. Its intermodal volumes increased 3% in the third quarter of 2026, supported by consumer demand, truck-market conditions and network improvements.

The companies highlighted projects including new Cincinnati-to-Atlanta service, East Edge double-stack clearance improvements connecting the Midwest and New England, and terminal investments in Ohio, Michigan, North Carolina and Illinois.

The agreement strengthens Norfolk Southern’s position in domestic intermodal while giving Schneider a larger eastern rail platform. For both companies, the partnership could support longer-term volume growth by offering shippers a more scalable and cost-efficient alternative to over-the-road freight.

💬 🔗

Global Finance News 11-01-26

Schneider National reported weaker-than-expected results for the fourth quarter of 2025 as softer market conditions and a shortened peak season weighed on volumes and profitability.

The company posted operating revenues of $1.4 billion in the quarter, up from $1.3 billion a year earlier, but income from operations declined to $36.5 million from $42.4 million. Diluted earnings per share fell to $0.13 from $0.18, while adjusted diluted EPS also came in at $0.13 compared with $0.20 in the prior year. Management cited muted demand starting in November, higher third-party carrier costs, unplanned customer shutdowns, and rising healthcare expenses as key headwinds, partly offset by some improvement late in December.

For the full year, Schneider generated operating revenues of $5.67 billion and adjusted EBITDA of $617.5 million. Looking ahead, the company issued full-year 2026 adjusted diluted EPS guidance of $0.70 to $1.00 and net capital expenditures guidance of $400 to $450 million. Schneider also highlighted ongoing cost savings initiatives, growth in dedicated and intermodal services, and continued capital returns through dividends and a newly authorized $150 million share repurchase program.

Source: Schneider National, Inc.

💬 🔗

WS Investor 01-30-26

Schneider National Reports Q3 2025 Results; Maintains Full-Year Outlook Despite Softer Market

Schneider National (NYSE: SNDR) reported third-quarter 2025 operating revenues of $1.45 billion, up 10% from $1.32 billion a year earlier, driven by the acquisition of Cowan Systems and steady growth across its segments. Income from operations fell 18% to $35.3 million due to higher claims costs and inflationary pressures. Net income declined 37% to $19.4 million, with diluted EPS at $0.11 versus $0.17 in 2024. Adjusted EPS was $0.12.

Truckload segment revenues rose 17% to $624.5 million, fueled by a 22% increase in Dedicated volume from Cowan’s integration, though margins tightened due to startup inefficiencies and higher insurance and equipment costs. Intermodal revenue grew 6% to $281.4 million on 10% volume growth, while Logistics sales rose 6% to $332.1 million but faced weaker brokerage activity.

Schneider reaffirmed its full-year adjusted EPS guidance of approximately $0.70 and net capital expenditures of about $300 million. CEO Mark Rourke highlighted resilient performance despite sub-seasonal freight trends, noting ongoing progress in structural efficiency initiatives and growth in Dedicated and Intermodal operations.

💬 🔗

Global Finance News 10-30-25

Schneider National, Inc. reported its fourth-quarter 2024 financial results, showing a decline in operating revenues to $1.34 billion from $1.37 billion in the same period in 2023. However, income from operations increased 35% to $42.4 million, with diluted earnings per share rising to $0.18 from $0.15 in the prior year. Adjusted diluted earnings per share were $0.20, compared to $0.16 in 2023. The company provided 2025 guidance for adjusted diluted earnings per share between $0.90 and $1.20, with net capital expenditures projected at $400-$450 million.

CEO Mark Rourke noted that seasonal patterns returned to the freight market, and demand showed improvement as carriers exited the market. The company's Truckload segment saw revenue growth, particularly in its Dedicated business, which now represents 70% of the segment following the acquisition of Cowan Systems. Intermodal achieved its second consecutive quarter of year-over-year earnings growth, while Logistics saw a 39% increase in income from operations.

Schneider ended the year with $526.8 million in debt, up from $302.1 million in 2023, and $117.6 million in cash and cash equivalents. Free cash flow increased by $199.6 million year-over-year, despite lower capital expenditures on transportation equipment.

Looking ahead, Schneider expects improving freight market conditions in 2025, with a focus on margin restoration and long-term growth. The company aims to improve Truckload profitability, expand Intermodal volumes, and continue leveraging technology in its Logistics segment.

💬 🔗

European Investor 01-30-25

Schneider National, Inc. has announced a quarterly cash dividend for the first fiscal quarter of 2025. The company's board of directors approved the dividend on January 27, 2025, setting the amount at $0.095 per share for holders of its Class A and Class B common stock. Shareholders of record as of the close of business on March 14, 2025, will be eligible to receive the dividend, which is scheduled for payment on April 9, 2025.

💬 🔗

The Investor 01-29-25

Load More

NASDAQ:AMDFollow

Track all markets on TradingView - Prices are not updated in real time

AMD Expands Meta AI Partnership as Helios Systems Enter Deployment

AMD (NASDAQ: AMD) said it is expanding its strategic partnership with Meta across CPUs, GPUs, networking, systems and software as the two companies scale infrastructure for Meta’s AI and superintelligence workloads.

Initial AMD Helios rack-scale systems have been installed and are being tested by Meta ahead of a broader deployment. AMD EPYC processors already support Meta’s Muse AI agent, while Meta has deployed millions of EPYC CPUs across multiple generations and is a lead customer for sixth-generation EPYC processors.

AMD Instinct GPUs are also being used in production for training, ranking and recommendation workloads. Meta was an early definition customer for the MI450 architecture and plans to deploy a custom Instinct GPU optimized for its workloads. The collaboration is also influencing future AMD platforms, including the MI500 series and next-generation rack-scale systems.

On the software side, AMD and Meta are working together on ROCm, PyTorch and Triton, including optimization of large-scale AI training on MI350X GPUs. AMD also said its hardware provides Day-0 support for Meta models including Muse Spark Open and Muse Glimmer.

The companies said they are aligning future silicon, software and system roadmaps around Meta workloads, with the goal of building integrated AI infrastructure at gigawatt scale. AMD will also invest $1 billion in Meta’s equity offering.

The announcement strengthens AMD’s position as a supplier to one of the world’s largest AI infrastructure buyers and expands its role beyond individual processors into full rack-scale systems, networking and software.

💬 🔗

Global Finance News 11-01-26

AMD Gains as Citi Lifts Price Target to $800, Mizuho Raises Target to $705

Advanced Micro Devices (NASDAQ: AMD) shares rose about 2.7% on Tuesday after analysts issued bullish updates tied to the company’s expanding role in AI infrastructure and server CPUs.

Citi analyst Atif Malik reiterated a Buy rating on AMD and raised his price target to $800 from $575. Malik said Meta’s newly launched Muse AI agent could significantly increase compute demand and strengthen AMD’s position in the server CPU market.

Citi now estimates the CPU total addressable market could grow from $29 billion in 2025 to $300 billion by 2030, implying a roughly 60% compound annual growth rate.

Malik expects AMD to be the primary beneficiary of what he described as a “CPU renaissance,” with Meta viewed as one of AMD’s largest server customers. He also argued that agentic AI could require orders of magnitude more computing power than traditional chatbot workloads (yahoofinance).

Mizuho also became more bullish on AMD, with analyst Vijay Rakesh raising the firm’s price target to $705 from $580 while maintaining an Outperform rating.

The analyst optimism follows a strong run of fundamental catalysts for AMD. The company recently reported record second-quarter revenue of $11.5 billion, up 50% year over year, while Data Center revenue more than doubled to $6.7 billion on strong demand for EPYC server processors and Instinct AI accelerators (yahoofinance).

AMD is also preparing its next generation of AI hardware, including the Instinct MI450 GPUs, 6th Gen EPYC Venice CPUs and Helios rack-scale AI systems.

The combination of higher analyst price targets, expectations for rapidly expanding AI-driven CPU demand and continued strength in AMD’s data center business appears to be supporting the stock’s latest move higher.

💬 🔗

The Investor 10-06-26

AMD Rose 2.2% After Piper Sandler Initiated Coverage With $600 Target

Advanced Micro Devices (NASDAQ: AMD) shares rose 2.2% yesterday after Piper Sandler initiated coverage of the chipmaker with an Overweight rating and a $600 price target.

AMD has built a strong position in the rapidly expanding AI and data-center market through its Instinct accelerators, EPYC server processors and increasingly complete rack-scale AI infrastructure. Data Center revenue more than doubled year over year to $6.7 billion in the second quarter, driven by strong demand for EPYC processors and Instinct MI350-series GPUs.

The company is also expanding its position in large-scale AI infrastructure. Its latest portfolio includes the MI400-series accelerators, sixth-generation EPYC CPUs and Helios rack-scale systems, giving AMD exposure across AI training, inference and agentic workloads. Major AI and cloud customers working with AMD technology include OpenAI, Meta, Microsoft and Anthropic.

AMD’s combination of accelerating data-center growth, a broader AI product portfolio and expanding hyperscale deployments provides a strong fundamental backdrop as the company competes for a larger share of global AI infrastructure spending.

💬 🔗

European Investor 09-16-26

AMD Stock Rises 3.5% as CLSA Reiterates Outperform Rating With $710 Price Target

Advanced Micro Devices (NASDAQ: AMD) shares rose 3.5% to $523.37 on Wednesday as CLSA reiterated its Outperform rating on the semiconductor company.

CLSA maintained a $710 price target on AMD, implying approximately 36% upside from the stock price shown.

The reiterated bullish rating comes as AMD remains a major beneficiary of growing investment in artificial intelligence infrastructure, with investors closely watching the company’s ability to expand its position in the AI accelerator market.

AMD shares have attracted strong investor attention as the company competes for a larger share of AI computing demand while continuing to expand its data center processor business.

💬 🔗

WS Investor 09-09-26

AMD, Cisco and HUMAIN Expand Saudi AI Infrastructure With Instinct GPUs

AMD (NASDAQ: AMD), Cisco (NASDAQ: CSCO) and Saudi Arabia’s HUMAIN announced Monday that their first AMD-powered AI infrastructure is now operational in the Kingdom, marking a major step in their plans to build large-scale sovereign AI capacity.

The production system uses AMD Instinct MI355X GPUs and EPYC CPUs alongside Cisco Silicon One networking and 800G optics. HUMAIN is already using the infrastructure to provide GPU-as-a-service for AI workloads ranging from model training to inference.

The companies also announced the next major phase of the project. Beginning in 2027, they plan to deploy up to 250 megawatts of additional AI infrastructure based on AMD Instinct MI400 Series GPUs, EPYC processors and ROCm software, combined with Cisco networking technology. Capacity is expected to begin coming online in the second half of 2027.

The expansion forms part of the previously announced AMD-Cisco-HUMAIN joint venture, which remains on track to deploy up to 1 gigawatt of AI infrastructure by 2030. The companies said strong customer demand is supporting the buildout.

The project is particularly significant for AMD as it expands the footprint of its Instinct accelerators in large-scale AI data centers, competing for a greater share of a market currently dominated by NVIDIA. For Cisco, the project provides another major opportunity for its high-speed networking technology as AI clusters become larger and more demanding.

The partnership also supports Saudi Arabia’s ambition to become a major global AI infrastructure hub, with locally operated computing capacity designed to give governments and enterprises greater control over their data, models and AI systems.

💬 🔗

The Investor 08-31-26

AMD Upgraded to Strong Buy at Raymond James as Price Target Jumps to $641

Advanced Micro Devices (NASDAQ: AMD) received a bullish analyst upgrade Tuesday, with Raymond James raising its rating to Strong Buy from Outperform and lifting its price target to $641 from $565.

Analyst Simon Leopold's new target represents substantial upside from AMD's recent price of about $477.14.

Why the Upgrade Matters

The upgrade reinforces optimism around AMD's position in the rapidly expanding AI and data-center semiconductor market.

AMD has become one of the most important challengers to Nvidia in AI accelerators, while also maintaining a strong presence in server CPUs through its EPYC product line. The company's growing exposure to hyperscale data centers, enterprise AI infrastructure and next-generation computing gives it significant leverage to continued AI capital spending.

The higher price target suggests Raymond James sees stronger long-term earnings potential as AMD expands its AI product portfolio and competes for a larger share of accelerator and data-center spending.

The shift from Outperform to Strong Buy is also notable because it signals increased conviction rather than simply maintaining an already-positive stance.

Investors will now focus on AMD's AI accelerator shipments, data-center revenue growth, margins and its ability to gain market share as the global AI infrastructure buildout continues.

💬 🔗

WS Investor 08-25-26

MD Acquires Taalas to Strengthen AI Inference Chip Portfolio

AMD (NASDAQ: AMD) has agreed to acquire Taalas, a Toronto-based developer of specialized AI inference silicon, as the chipmaker expands its technology portfolio for the rapidly growing AI inference market.

Founded in 2023, Taalas develops technology designed specifically to optimize AI inference dataflows, reducing compute and memory bottlenecks associated with more general-purpose architectures. AMD said the technology could provide significant improvements in inference performance and efficiency.

The acquisition is intended to complement AMD's broader full-stack AI platform, which includes Instinct GPUs, EPYC CPUs, ROCm software and Helios rack-scale systems.

## AMD Targets Growing AI Inference Demand

AMD plans to integrate Taalas' technology into its accelerator roadmap and combine it with Instinct GPUs to develop system-level AI solutions.

The strategy reflects the industry's increasing focus on inference — the process of running trained AI models — as artificial intelligence moves into high-volume, real-time applications. More specialized silicon can potentially lower the computing, memory and energy requirements associated with deploying increasingly large AI models.

AMD said Taalas' engineering team will also strengthen its AI capabilities while expanding the company's existing semiconductor and AI presence in Canada.

Financial terms of the transaction were not disclosed. The acquisition remains subject to customary closing conditions and regulatory approvals.

The deal represents another step in AMD's effort to build a broader AI computing platform and compete across multiple layers of the AI infrastructure market, with Taalas adding specialized inference technology alongside AMD's existing GPU-based accelerator portfolio.

💬 🔗

Global Finance News 08-07-26

## AMD Stock Falls 10% After Hours Despite Record Revenue as Investors Focus on AI Expectations

Advanced Micro Devices (NASDAQ: AMD) shares fell 10% in after-hours trading Tuesday, despite reporting record second-quarter revenue and earnings, as investors appeared to take profits following high expectations for the company's AI business.

AMD delivered record second-quarter revenue of $11.5 billion, up 50% year over year, while non-GAAP earnings per share surged 246% to $1.66. Gross margin expanded to 56%, and operating income climbed to $3.1 billion, reflecting strong profitability as AI demand continued to accelerate.

The Data Center business remained AMD's primary growth engine. Segment revenue more than doubled, rising 107% year over year to $6.7 billion, driven by robust demand for EPYC server processors and Instinct AI accelerators. The segment accounted for approximately 58% of total company revenue during the quarter. Meanwhile, the Client business continued to perform well with Ryzen processor demand driving 23% growth, although Gaming revenue declined 31% due to weaker semi-custom sales.

Management highlighted a series of major AI announcements during the quarter, including the launch of the Helios AI rackscale platform, the new Instinct MI400 GPU family, sixth-generation EPYC processors, and expanded partnerships with leading AI companies including OpenAI, Microsoft, Meta, Anthropic, Oracle, and others. AMD also announced new collaborations designed to accelerate AI infrastructure deployments and broaden adoption of its hardware and software ecosystem.

Looking ahead, the company forecast third-quarter revenue of approximately $13.0 billion, representing roughly 41% year-over-year growth and another sequential acceleration, while maintaining an expected non-GAAP gross margin of approximately 56%.

Despite the strong financial performance and optimistic outlook, the stock declined after hours as investors appeared to have anticipated another exceptional quarter following AMD's strong rally and elevated expectations surrounding AI infrastructure spending. While the earnings reinforced AMD's growing position in AI computing, the market reaction suggests investors are demanding increasingly larger upside surprises from leading semiconductor companies.

💬 🔗

WS Investor 08-04-26

Semiconductor Stocks Fall as China's Chip Breakthrough Pressures Nvidia and the AI Sector

Semiconductor stocks came under pressure on Monday, dragging the Nasdaq lower as investors weighed China's rapidly advancing semiconductor industry against the latest developments in the global AI infrastructure race. Nvidia led the sector's decline, falling more than 4%, while weakness spread across AI and memory chipmakers.

The latest catalyst on the AI front came after reports that Nvidia is in talks to provide roughly $250 billion in financing guarantees for OpenAI's massive AI data center project in Ohio. The proposed 10-gigawatt facility would rank among the world's largest AI infrastructure projects, underscoring the enormous capital being committed to artificial intelligence. While the news reinforces long-term demand for AI hardware, it also highlights the rapidly evolving competitive landscape and the unprecedented scale of investment required across the industry.

Investor sentiment was also weighed down by developments in China. ChangXin Memory Technologies (CXMT), China's largest memory chipmaker, surged more than 400% in its Shanghai trading debut following Asia's largest IPO of 2026. The emergence of another major Chinese chipmaker renewed concerns that global competition in memory and AI-related semiconductors will intensify. Those concerns were particularly significant for Nvidia, whose growth opportunities in China have already been constrained by U.S. export restrictions.

The weakness extended across the broader semiconductor sector. Memory-related companies including Sandisk, Micron Technology, Western Digital, and SK Hynix posted notable declines, while ASML, AMD, Intel, Marvell Technology, Super Micro Computer, and Taiwan Semiconductor Manufacturing Co. (TSMC) also traded lower as investors reassessed the industry's competitive outlook.

Despite Monday's selloff, the semiconductor industry's long-term fundamentals remain supported by accelerating AI adoption and record investment in data center infrastructure. However, the combination of elevated valuations, China's rapid technological progress, and an increasingly competitive global landscape prompted investors to lock in profits following the sector's strong rally.

💬 🔗

European Investor 07-27-26

AMD Stock Rises 3.8% as China AI Chip Approval News and Analyst Price Target Increases Lift Sentiment

Advanced Micro Devices (NASDAQ: AMD) shares climbed 3.8% on Tuesday after receiving fresh support from Wall Street analysts and a Reuters report that another Chinese company has obtained U.S. approval to purchase AMD's advanced AI chips.

Bank of America raised its price target on AMD to $620 from $550 while maintaining a Buy rating. Meanwhile, KeyBanc increased its target price to $725 from $530 and reiterated its Overweight rating, reflecting growing confidence in AMD's long-term AI growth prospects.

According to Reuters, the U.S. government approved Zhuhai Hengqin Yunxiang Zhisheng Network Technology to purchase certain AMD AI accelerators that compete with Nvidia's H200 chips. The report added that ZTE Kangxun Telecom and server maker Maginfra also received approval to purchase Nvidia's H200 processors. These approvals follow similar authorizations granted in May to major Chinese technology companies, including Alibaba, Tencent, ByteDance, and JD*com, suggesting Washington may be selectively easing restrictions on advanced AI chip exports to China.

The Reuters report was viewed as a positive development for AMD, as China remains an important long-term market for AI infrastructure despite ongoing export controls. The latest approvals could allow AMD to capture additional demand from Chinese cloud providers and enterprise customers while expanding its presence in one of the world's largest AI markets.

The broader semiconductor sector also traded higher, supported by expectations of sustained AI infrastructure spending and easing inflation data that reinforced hopes for lower U.S. interest rates. The combination of improving policy developments, stronger access to the Chinese market, and renewed analyst optimism helped lift AMD shares alongside other AI chipmakers.

Investors will continue watching for further developments in U.S. export policy, enterprise AI spending trends, and AMD's execution in the increasingly competitive AI accelerator market, where it continues to challenge Nvidia for market share.

💬 🔗

The Investor 07-14-26

Load More

10-09-26Global Finance News

10-07-26European Investor

10-06-26The Investor

09-25-26WS News

09-25-26Global Finance News

NASDAQ:REGNFollow

Track all markets on TradingView - Prices are not updated in real time

Regeneron Q3 Revenue Jumps 36% as Dupixent, EYLEA HD and Libtayo Drive Growth

Regeneron Pharmaceuticals (NASDAQ: REGN) reported a strong third quarter of 2026, with revenue rising 36% year over year to $5.1 billion as key products delivered record sales growth.

Dupixent global net sales, recorded by Sanofi, increased 35% to $6.5 billion. EYLEA HD U.S. sales rose 62% to $699 million, while Libtayo global sales jumped 51% to $550 million.

Profit growth was also strong. GAAP net income increased 33% to $1.95 billion, while GAAP EPS rose 35% to $18.45. Non-GAAP net income climbed 67% to $2.15 billion, with adjusted EPS up 70% to $20.07.

Regeneron also expanded its antibody collaboration with Sanofi to include several next-generation, long-acting immunology antibodies. The agreement includes a $1.0 billion upfront payment that Regeneron expects to recognize as collaboration revenue in the fourth quarter, plus up to $7.0 billion of potential future milestones.

Pipeline momentum remained significant. Pasatru was approved by the FDA for fibrodysplasia ossificans progressiva, while Regeneron is advancing programs in multiple myeloma, lymphoma, obesity, MASH, POTS and ovarian cancer. The company expects an FDA decision for cemdisiran in generalized myasthenia gravis in November 2026.

For full-year 2026, Regeneron raised its expected gross margin on net product sales to approximately 80% on a GAAP basis and about 86% on a non-GAAP basis, while lowering expected SG&A expenses. R&D guidance was raised modestly as the company continues investing in its clinical pipeline.

Overall, the quarter showed broad-based commercial strength, substantial earnings growth and continued pipeline progress, with the expanded Sanofi partnership providing an additional near-term revenue catalyst.

💬 🔗

Global Finance News 11-01-26

Regeneron and Sanofi Expand Immunology Alliance in Deal Worth Up to $8 Billion

Regeneron and Sanofi expanded their long-running immunology collaboration to include four next-generation, long-acting antibody programs targeting key pathways involved in type 2 inflammation.

The expanded alliance includes REGN20423, a long-acting IL-13 monoclonal antibody currently in Phase 1 development for atopic dermatitis, along with a long-acting IL-4xIL-13 bispecific antibody and two additional antibodies targeting IL-4 and IL-4Rα. The latter three programs are expected to enter clinical development in 2027.

Under the agreement, Regeneron will receive $1 billion upfront and could earn up to an additional $7 billion in development, regulatory and commercial milestone payments. The companies will share development and commercialization costs and split future global profits 50:50.

Regeneron will lead research and development, while Sanofi will lead global commercialization. The existing profit-sharing arrangement for Dupixent will remain unchanged.

The companies said the expanded collaboration builds on more than two decades of joint work that helped establish Dupixent as a major treatment across multiple type 2 inflammatory diseases, with more than 1.5 million active patients worldwide.

The deal strengthens both companies’ immunology pipelines and gives them a broader set of long-acting therapies that could potentially extend beyond Dupixent into the next generation of treatments for inflammatory diseases.

💬 🔗

WS Investor 10-01-26

Regeneron Stock Rises After Strong Q2 Results and Improved 2026 Outlook

Regeneron Pharmaceuticals (NASDAQ: REGN) shares rose 1% after the biotechnology company reported strong second-quarter results, driven by continued growth from Dupixent, EYLEA HD and Libtayo, while updating its full-year financial guidance.

Second-quarter revenue increased 17% year over year to $4.3 billion, while non-GAAP earnings per share rose 11% to $14.29. Although GAAP EPS declined to $12.23 due to acquired in-process research and development (IPR&D) charges, the company's underlying operating performance remained strong.

Flagship Medicines Continue to Deliver

Regeneron's commercial portfolio continued to post robust growth during the quarter. Global Dupixent sales, recorded by partner Sanofi, climbed 38% to a record $6.0 billion, while U.S. sales of EYLEA HD surged 52% to a record $596 million. Global Libtayo sales also reached a new high, increasing 30% to $489 million. Higher Dupixent sales lifted collaboration revenue from Sanofi by 51%, helping drive overall revenue growth.

The company also announced that the Sanofi Development Balance was fully repaid by the end of the second quarter, a milestone expected to increase collaboration profits beginning in the third quarter.

Pipeline Advances and Guidance Update

Regeneron reported multiple regulatory and clinical milestones during the quarter, including accepted FDA and EMA submissions for cemdisiran in generalized myasthenia gravis and several approvals and label expansions across its portfolio. Management also updated its 2026 financial guidance, including higher expected gross margins and lower projected SG&A and capital expenditures, reflecting confidence in the business outlook.

What to Watch

The modest share gain reflects investor confidence in Regeneron's expanding commercial portfolio and improving profitability. Going forward, investors will monitor continued adoption of EYLEA HD, sustained Dupixent growth, upcoming regulatory decisions for cemdisiran and the anticipated increase in collaboration profits following the repayment of the Sanofi Development Balance.

💬 🔗

WS Investor 07-30-26

Regeneron Pharmaceuticals reported strong first-quarter 2026 results, driven by robust product growth and continued pipeline expansion.

Revenue increased 19% year-over-year to $3.6 billion, reflecting solid demand across key therapies. Non-GAAP EPS reached $9.47, while GAAP EPS was $6.75, impacted by charges related to in-process R&D.

Growth was supported by Dupixent, whose global sales (reported by partner Sanofi) surged 33% to $4.9 billion. Meanwhile, EYLEA HD U.S. sales jumped 52% to $468 million, although combined EYLEA franchise sales declined 10%, reflecting product transition dynamics.

On the regulatory front, the company secured multiple approvals, including expanded indications for Dupixent and the approval of Otarmeni, a first-in-class gene therapy for genetic hearing loss.

Regeneron also announced a new $3 billion share buyback program, underscoring confidence in its long-term growth outlook.

Source: GlobeNewswire

💬 🔗

Global Finance News 04-30-26

Regeneron Pharmaceuticals announced an agreement with the U.S. government to lower drug costs and expand access to treatments, including providing its newly approved gene therapy Otarmeni for free in the United States. The therapy targets a rare genetic form of hearing loss and marks a significant step in improving patient access to advanced medicines.

Under the agreement, the company will align U.S. drug prices with those in other developed countries and reduce Medicaid pricing accordingly. It will also enable direct patient purchases of its cardiovascular drug Praluent through a government platform.

Regeneron said the initiative supports broader affordability while maintaining investment in domestic research, development, and manufacturing.

Source: GlobeNewswire

💬 🔗

The Investor 04-24-26

Regeneron reported positive Phase 3 results for its investigational therapy cemdisiran in patients with generalized myasthenia gravis (gMG), demonstrating rapid, deep, and sustained disease control. The NIMBLE trial met both its primary and key secondary endpoints at 24 weeks, showing significant improvements in daily functioning and muscle strength compared to placebo.

Patients receiving cemdisiran experienced clinically meaningful benefits within two weeks, with effects sustained throughout the study period. The therapy, administered subcutaneously every 12 weeks, also offers a reduced treatment burden compared to existing options.

The safety profile was generally consistent, with most adverse events mild to moderate and no new major safety concerns identified.

Regeneron has already submitted a U.S. regulatory application and plans additional filings in other regions, positioning cemdisiran as a potential first siRNA-based treatment for gMG.
Globe Newswire

💬 🔗

European Investor 04-21-26

Regeneron Pharmaceuticals and Telix Pharmaceuticals have entered into a strategic collaboration to develop and commercialize next-generation radiopharmaceutical therapies for cancer.

The partnership combines Regeneron’s antibody discovery and oncology expertise with Telix’s radiopharmaceutical development and manufacturing capabilities, targeting multiple solid tumor indications. The companies will jointly fund development and share profits under a 50/50 model, while also working on diagnostic tools to support patient selection and treatment monitoring.

Under the agreement, Telix will receive an upfront payment of $40 million, with potential additional milestone payments of up to $2.1 billion depending on development and commercialization outcomes.

The collaboration reflects growing industry interest in targeted radiopharmaceuticals as a promising approach in precision oncology, particularly for hard-to-treat cancers.
Globe Newswire

💬 🔗

European Investor 04-13-26

Sanofi and Regeneron Pharmaceuticals announced that the European Commission has approved Dupixent (dupilumab) for treating children aged 2 to 11 with chronic spontaneous urticaria (CSU), marking the first targeted therapy for this age group in the EU.

The approval expands Dupixent’s indication beyond adults and adolescents, offering a new option for young patients whose condition remains uncontrolled with standard antihistamine treatments. CSU is a chronic inflammatory skin disease characterized by severe itching and recurrent hives, significantly affecting quality of life.

The decision is based on results from the LIBERTY-CUPID clinical program, which showed that Dupixent significantly reduced disease activity compared with placebo and improved symptom control. Safety outcomes were consistent with the drug’s established profile across other indications.

With this latest authorization, Dupixent is now approved in the EU for children under 12 across multiple diseases linked to type 2 inflammation, further strengthening its position as a leading biologic therapy in immunology.

💬 🔗

Global Finance News 04-13-26

Regeneron Pharmaceuticals announced a strategic collaboration with TriNetX to access de-identified electronic health records from approximately 300 million patients worldwide.

The partnership will allow Regeneron to integrate TriNetX’s large-scale clinical data with its own genomic and proteomic datasets, significantly expanding its research database. The combined data is expected to accelerate drug discovery, improve clinical development, and support the training of AI-driven healthcare solutions.

As part of the agreement, Regeneron will invest up to $200 million in TriNetX, while ensuring compliance with global data privacy regulations such as HIPAA and GDPR.

The companies said the collaboration aims to advance precision medicine and enable new digital health innovations by leveraging one of the largest integrated health data ecosystems in the industry.
Globe Newswire

💬 🔗

Global Finance News 04-03-26

Sanofi and Regeneron announced that Japan has approved Dupixent (dupilumab) as the first targeted treatment for adults with moderate-to-severe bullous pemphigoid, a chronic inflammatory skin disease.

The approval is based on clinical trial data showing that patients receiving Dupixent were more than four times as likely to achieve sustained disease remission at 36 weeks compared with placebo (18% vs. 4%).

Dupixent, already approved in Japan for multiple inflammatory conditions, marks its seventh indication in the country, expanding its role in treating type 2 inflammatory diseases.

💬 🔗

Global Finance News 03-24-26

Load More

03-31-26Global Finance News

10-30-25Global Finance News

NYSE:GDFollow

Track all markets on TradingView - Prices are not updated in real time

General Dynamics Q3 Revenue Rises 13% as Defense Orders Drive Record Backlog

General Dynamics (NYSE: GD) reported strong third-quarter 2026 results, with revenue increasing 12.9% year over year to $14.6 billion and diluted EPS rising 15.7% to $4.49.

Operating earnings increased 14.7% to $1.5 billion, while operating margin expanded 20 basis points to 10.5%. Management said all four business segments delivered revenue growth during the quarter.

Order activity was exceptionally strong. General Dynamics received $98.8 billion of total orders, including $93.8 billion across its defense businesses. Large Marine Systems awards for Virginia- and Columbia-class submarines were major contributors.

Company-wide book-to-bill reached 6.8x, including 8.5x in the defense segments and 1.4x in Aerospace. Backlog ended the quarter at $220.3 billion, while total estimated contract value, including potential IDIQ awards and unexercised options, reached $270.7 billion.

Cash generation also remained solid. Operating cash flow totaled $1.7 billion, equal to 139% of net earnings. General Dynamics paid $429 million in dividends, invested $481 million in capital expenditures and reduced debt by $500 million during the quarter.

Overall, the results point to strong multi-year revenue visibility, particularly in defense, with submarine demand and broader military procurement driving a sharp increase in orders and backlog.

💬 🔗

Global Finance News 11-01-26

General Dynamics Stock Falls After Strong Q2 Results and Robust Defense Demand

General Dynamics (NYSE: GD) shares fall 1% on Wednesday after the defense contractor reported solid second-quarter results, highlighted by broad-based revenue growth, expanding margins, and strong order activity across all business segments.

The company reported second-quarter revenue of $14.1 billion, up 8.1% year over year, while diluted EPS increased 13.4% to $4.24. Operating earnings rose 11.9% to $1.5 billion, and operating margin expanded 40 basis points to 10.4%, reflecting improved execution across the business.

Growth was broad-based, with all four operating segments posting higher revenue. Aerospace and Marine Systems delivered particularly strong performance, achieving double-digit revenue growth and meaningful margin expansion as production rates increased to meet customer demand.

General Dynamics also generated strong cash flow during the quarter, producing $1.9 billion in operating cash flow, equivalent to 162% of net earnings. The company continued strengthening its balance sheet by reducing debt by nearly $500 million while returning $429 million to shareholders through dividends.

Demand remained exceptionally strong. The company secured $20 billion in new orders during the quarter, resulting in a company-wide book-to-bill ratio of 1.4, meaning new orders significantly exceeded revenue recognized during the period. Backlog increased to $136.5 billion, while total estimated contract value reached $186.9 billion, providing substantial long-term revenue visibility.

Management emphasized continued investment to expand production capacity in response to growing defense and aerospace demand, positioning the company to execute on its record backlog.

💬 🔗

The Investor 07-29-26

General Dynamics reported strong first-quarter 2026 results, driven by broad-based growth and robust order activity.

Revenue increased 10.3% year-over-year to $13.5 billion, with all four business segments contributing to the expansion. Profitability also improved, as diluted EPS rose 12% to $4.10, while operating margin stood at 10.5%.

The company generated strong cash flow, with $2.2 billion in operating cash—equivalent to 192% of net earnings—highlighting excellent cash conversion. During the quarter, General Dynamics returned capital to shareholders through $405 million in dividends and continued investing in its operations.

Order activity remained a key strength, with total orders reaching $26.6 billion and a solid book-to-bill ratio of 2.0, indicating strong future revenue visibility. The company ended the quarter with a substantial total estimated contract value of $188.4 billion, including a backlog of $130.8 billion.

Source: Company press release

💬 🔗

Global Finance News 04-30-26

Historical Returns For Stocks, Bonds, Cash, Housing & Gold (2025) - A Wealth of Common Sense

Updated long run returns through 2025.

(awealthofcommonsense.com)

💬 🔗

WS Investor 01-11-26

General Dynamics announced today that Danny Deep, currently executive vice president, Global Operations, has been promoted to president of the company.

💬 🔗

Global Finance News 12-07-25

General Dynamics Reports Strong Q3 2025 Results with Double-Digit Growth and Robust Order Activity

General Dynamics (NYSE: GD) reported third-quarter 2025 revenue of $12.9 billion, up 10.6% from the same period last year, driven by strong performance across all business segments. Diluted EPS rose 15.8% to $3.88, and operating earnings increased 12.7% to $1.3 billion, resulting in an operating margin of 10.3%, up 20 basis points year-over-year.

CEO Phebe Novakovic highlighted the company’s broad-based growth, noting particularly strong results in the Aerospace segment, which grew 30.3% in revenue and expanded margins by 100 basis points as demand for business jets remained robust.

Operating cash flow reached $2.1 billion, equal to 199% of net earnings. General Dynamics returned $403 million to shareholders through dividends, invested $212 million in capital expenditures, and ended the quarter with $8 billion in debt and $2.5 billion in cash.

Order activity was exceptionally strong, with $19.3 billion in new orders and a book-to-bill ratio of 1.5-to-1. Total estimated contract value climbed to $167.7 billion, including $109.9 billion in backlog and $57.8 billion in potential contract value from unfunded and unexercised options.

💬 🔗

The Investor 10-25-25

General Dynamics Wins U.S. Navy Contract for Additional DDG 51 Destroyer

General Dynamics Bath Iron Works, a division of General Dynamics (NYSE: GD), announced that the U.S. Navy has exercised an option to purchase an additional Arleigh Burke-class (DDG 51) destroyer under the multi-year contract awarded in 2023.

President Charles F. Krugh credited the Bath Iron Works team for construction improvements and acknowledged Congressional support in securing the ship through the FY2025 Defense Appropriations Bill.

Bath Iron Works is currently building several destroyers, including both Flight IIA and Flight III variants. General Dynamics employs over 110,000 people worldwide and reported $47.7 billion in revenue for 2024.

💬 🔗

WS Investor 08-01-25

General Dynamics Appoints Danny Deep as EVP of Global Operations

General Dynamics has promoted Danny Deep to Executive Vice President of Global Operations, effective June 4, 2025. Previously EVP of Combat Systems, Deep will now oversee global operational strategy. His new compensation includes a $1.2 million base salary, a 130% target annual incentive, and equity-based long-term incentives aligned with the company’s 2025 proxy statement.

💬 🔗

M

ME NEWS 06-10-25

The board of directors of General Dynamics (NYSE: GD) today declared a regular quarterly dividend of $1.50 per share on the company's common stock, payable August 8, 2025, to shareholders of record on July 3, 2025

💬 🔗

WS News 06-06-25

General Dynamics Shareholders Approve Board Slate and Executive Pay, Reject Human Rights Proposal

At its annual meeting, General Dynamics shareholders elected all 13 director nominees, including CEO Phebe N. Novakovic and former Secretary of Defense James N. Mattis. Each candidate received strong support, with Mark M. Malcolm earning the highest approval. Shareholders also approved KPMG LLP as the company’s independent auditor for 2025 and endorsed the company’s executive compensation on an advisory basis. However, a shareholder proposal requesting a human rights impact assessment report was decisively rejected by over 94% of votes cast.

💬 🔗

M

ME NEWS 05-12-25

Load More

09-29-25The Investor

NYSE:XOMFollow

Track all markets on TradingView - Prices are not updated in real time

ExxonMobil Q3 Earnings Rise as Refining Strength and Cost Savings Offset Lower Upstream Results

ExxonMobil (NYSE: XOM) reported third-quarter 2026 earnings of $15.4 billion, or $3.72 per share, while adjusted earnings reached $17.5 billion, or $4.23 per share.

Cash generation remained strong, with operating cash flow of $25.7 billion and free cash flow of $19.1 billion. ExxonMobil returned $9.4 billion to shareholders during the quarter, including $4.3 billion of dividends and $5.1 billion of share repurchases.

Energy Products was the strongest sequential contributor. Segment earnings increased to $7.17 billion from $5.47 billion in the second quarter, while adjusted earnings more than doubled to $9.05 billion. Management cited stronger refining margins, high utilization and strong operational performance, including 100% crude-unit utilization at its U.S. Gulf Coast refineries.

Upstream earnings declined sequentially to $7.09 billion from $7.93 billion, reflecting lower commodity prices and the impact of Guyana entitlement timing. Production remained high at approximately 4.5 million oil-equivalent barrels per day, supported by Guyana, the Permian Basin and Golden Pass LNG.

Year-to-date earnings reached $34.1 billion, compared with $22.3 billion a year earlier, while adjusted earnings increased to $41.0 billion from $22.5 billion. ExxonMobil said structural cost savings since 2019 have reached $16.9 billion.

The company also continued strengthening its balance sheet, reducing net debt by nearly $11 billion year to date. ExxonMobil increased its quarterly dividend to $1.07 per share, extending its annual dividend-growth streak to 44 consecutive years, and announced plans for approximately $20 billion of share repurchases in 2027, assuming reasonable market conditions.

Overall, the quarter showed that stronger refining profitability, disciplined cost control and high cash generation are helping offset softer sequential upstream conditions while supporting continued shareholder distributions.

💬 🔗

Global Finance News 11-01-26

ExxonMobil Shares Fall Despite Strong Q2 Earnings and Record Production

ExxonMobil (NYSE: XOM) shares fell 2.6% on Friday despite reporting strong second-quarter results, as lower oil prices and weakness across the energy sector weighed on sentiment.

The company reported second-quarter earnings of $14.5 billion, or $3.48 per share, while adjusted earnings came in at $14.7 billion, or $3.52 per share. Operating cash flow reached $23.6 billion and free cash flow totaled $17.2 billion, allowing ExxonMobil to return $9.4 billion to shareholders through dividends and share repurchases.

Record Production and Operational Performance

ExxonMobil reported its highest upstream production in more than two decades, excluding Middle East disruptions. The company also achieved record production in the Permian Basin, maintaining its long-term production growth plans, while its fifth Guyana FPSO departed for deployment ahead of a planned fourth-quarter startup that will add 250,000 barrels per day of production capacity.

The company also set a record for second-quarter diesel production, supported by strong utilization along the U.S. Gulf Coast and continued operational efficiency.

Continued Investment and Cost Savings

ExxonMobil highlighted cumulative structural cost savings of $16.3 billion, which it said exceed those of all other international oil companies combined. The company invested $13 billion year-to-date in growth projects and announced a final investment decision to expand its Proxxima blending facility in Louisiana. ExxonMobil also declared a third-quarter dividend of $1.03 per share.

What to Watch

Despite the earnings beat, investors remained focused on weaker crude oil prices, which pressured the broader energy sector. Going forward, markets will monitor oil price trends, production growth from Guyana and the Permian Basin, refining margins and ExxonMobil's continued execution of its long-term investment strategy.

💬 🔗

The Investor 07-31-26

Exxon Mobil Edges Higher After Bank of America Upgrades Stock to Buy

Exxon Mobil (NYSE: XOM) shares rose modestly on Tuesday after Bank of America upgraded the energy giant to Buy from Neutral and set a $154 price target.

The upgrade comes as oil markets adjust to a changing geopolitical landscape following the recent U.S.-Iran agreement, which has helped push crude prices lower by reducing concerns about supply disruptions in the Middle East. Despite the decline in oil prices, Bank of America appears to see value in Exxon Mobil's diversified operations, strong balance sheet, and ability to generate significant cash flow across commodity cycles.

The firm's bullish stance suggests confidence that Exxon can continue delivering shareholder returns through dividends and buybacks while benefiting from its scale, low-cost production base, and growing portfolio of high-return projects, particularly in Guyana and the Permian Basin.

The relatively muted share-price reaction indicates that investors are balancing the positive analyst upgrade against a softer near-term outlook for crude prices. However, Exxon remains one of the industry's strongest cash generators and is widely viewed as being better positioned than many peers to navigate periods of commodity price volatility.

With Bank of America's $154 price target implying meaningful upside from current levels, the upgrade highlights continued optimism that Exxon can create value even as energy markets transition from geopolitical-driven supply concerns toward a greater focus on underlying demand and economic growth trends.

💬 🔗

Global Finance News 06-16-26

Exxon Mobil Shares Fall as Oil Prices Slide on U.S.-Iran Peace Deal Optimism

Exxon Mobil (NYSE: XOM) shares fell 4% after TD Cowen reiterated its Buy rating, as investors focused on the sharp decline in crude oil prices following reports that the United States and Iran are moving closer to a formal peace agreement.

Brent crude dropped nearly 5% to around $83 per barrel after news that the two countries had reached a framework agreement aimed at ending hostilities and reopening the Strait of Hormuz, a critical route for global energy shipments. The decline reflects the unwinding of the geopolitical risk premium that had supported oil prices in recent months.

Energy stocks broadly came under pressure as lower oil prices could reduce near-term earnings expectations for major producers. Exxon, one of the world's largest integrated oil companies, is also sensitive to changes in crude prices.

Despite the pullback, TD Cowen maintained its Buy rating on Exxon, arguing that the company's long-term growth strategy remains intact. The firm continues to see value in Exxon’s diversified portfolio, strong balance sheet, and production growth initiatives, even as near-term commodity prices fluctuate.

The market reaction suggests investors are prioritizing the immediate impact of falling oil prices over analyst optimism. Going forward, Exxon shares are likely to remain closely tied to developments surrounding the U.S.-Iran negotiations and the direction of global crude markets.

💬 🔗

European Investor 06-15-26

Exxon Mobil Corporation (NYSE: XOM) will release its first quarter 2026 financial results on Friday, May 1, 2026

💬 🔗

WS Investor 04-17-26

ExxonMobil Board Unanimously Recommends Redomiciling the Company from New Jersey to Texas

💬 🔗

European Investor 04-11-26

Exxon Mobil Corporation announced that its board unanimously recommends moving the company’s legal domicile from New Jersey to Texas, aligning its legal base with where its headquarters and core operations have been located since 1989. The proposal, which requires shareholder approval at the 2026 annual meeting, would not change ExxonMobil’s operations, management, assets, strategy, or employee locations.

The company said Texas offers a regulatory and legal environment more supportive of business, including modern corporate statutes and the Texas Business Court designed to resolve complex corporate disputes efficiently. CEO Darren Woods stated that aligning the company’s legal home with its operating base in a state closely connected to its workforce and operations could help maximize shareholder value.

ExxonMobil currently has a large presence in Texas, where about 30% of its global employees and roughly 75% of its U.S. workforce are located. The company’s historical link to New Jersey dates back to the incorporation of Standard Oil of New Jersey in 1882, but the board noted it has not held a meeting in the state for more than four decades.
Source: Business Wire

💬 🔗

European Investor 03-10-26

ExxonMobil reported strong full-year 2025 results, supported by record production, disciplined cost control, and robust shareholder returns.

The company generated earnings of $28.8 billion and cash flow from operations of $52.0 billion in 2025, with earnings per share of $6.70, or $6.99 excluding identified items. Upstream production reached its highest level in more than 40 years, while refinery throughput set a new record, enabling total shareholder distributions of $37.2 billion, split between $17.2 billion in dividends and $20.0 billion in share repurchases.

ExxonMobil also delivered all 10 key projects on schedule, added an estimated $3 billion in earnings capacity on a constant price basis, and achieved $15.1 billion in cumulative structural cost savings since 2019. The company confirmed progress toward its 2030 greenhouse gas and flaring intensity reduction targets and announced a quarterly dividend of $1.03 per share, extending its dividend growth streak to 43 consecutive years.

💬 🔗

Global Finance News 01-30-26

Exxon Mobil Corporation announced that it will release its fourth-quarter 2025 financial results on Friday, January 30, 2026, before U.S. markets open.

Source: Business Wire

💬 🔗

Global Finance News 01-14-26

Exxon Mobil Corporation outlined key factors expected to influence fourth-quarter 2025 results relative to the third quarter, emphasizing that these are directional considerations rather than earnings guidance.

Management expects lower liquids and gas prices to weigh on upstream results, partially offset by stronger industry margins and timing effects. Planned and seasonal factors include impacts from scheduled maintenance, year-end inventory effects, and identified items such as divestment gains, impairments, restructuring charges, and tax-related items across segments.

The company noted that these estimates exclude underlying operating performance and other variables such as foreign exchange, unplanned downtime, or broader macroeconomic shifts. ExxonMobil plans to release full 4Q 2025 financial results on January 30, 2026, via its website and an SEC Form 8-K filing.

💬 🔗

The Investor 01-08-26

Load More

07-31-26The Investor

06-16-26Global Finance News

06-16-26Global Finance News

05-01-26The Investor

04-08-26WS Investor

NASDAQ:INTCFollow

Track all markets on TradingView - Prices are not updated in real time

Intel Plunges 28% as Weak Q4 Outlook and PC Slowdown Overshadow Strong Q3 Results

Intel (NASDAQ: INTC) shares plunged about 28% following its third-quarter 2026 earnings report as investors focused on a sharply weaker fourth-quarter outlook, lower expected margins and management’s warning that the PC slowdown could continue through at least the first half of 2027.

Third-quarter results themselves were strong. Revenue increased 21% year over year to $16.5 billion, while non-GAAP EPS more than doubled to $0.52 from $0.23. Non-GAAP gross margin improved to 44.1% from 40.0%, and adjusted operating margin expanded to 19.6% from 11.2%.

Data Center and AI was the standout business, with revenue surging 78% to $7.3 billion, representing Intel’s strongest data center revenue growth in 15 years. Intel Foundry revenue also increased 58% to $6.7 billion. However, Client Computing and Physical AI revenue declined 5% to $8.1 billion, highlighting weakness in the PC market.

The main concern was Intel’s fourth-quarter outlook. The company expects revenue of $15.0 billion to $16.0 billion, implying a sequential decline from Q3’s $16.5 billion. More importantly, non-GAAP gross margin is expected to fall sharply to 38.0% from 44.1% in Q3, while adjusted EPS is projected at just $0.25 compared with $0.52 in the third quarter.

Management also warned that the PC slowdown is expected to continue through at least the first half of next year. At the same time, Intel plans to increase investments in capacity and working capital to address what it described as extraordinary demand for Xeon processors.

The 28% selloff therefore appears to reflect a substantial reset in near-term expectations. Despite strong Q3 revenue growth and accelerating data center demand, investors reacted negatively to the projected sequential revenue decline, roughly six-percentage-point contraction in adjusted gross margin, weaker Q4 earnings and prolonged PC-market headwinds.

💬 🔗

Global Finance News 11-01-26

Applied Materials and Intel Expand Collaboration to Accelerate AI Chip Manufacturing

Applied Materials (NASDAQ: AMAT) and Intel (NASDAQ: INTC) announced an expanded collaboration aimed at accelerating development of next-generation semiconductor technologies for AI computing.

The companies will work together at Applied Materials’ new EPIC Center in Silicon Valley and Intel’s R&D campus in Hillsboro, Oregon, focusing on advanced transistors, interconnects and packaging technologies. The goal is to shorten development cycles and speed the transition of new semiconductor innovations from research into high-volume manufacturing.

The collaboration includes work on next-generation materials, process technologies and device architectures for advanced logic nodes, as well as interconnect scaling and Foveros-based 3D packaging. These technologies are designed to improve interconnect density, power delivery and thermal performance for high-performance AI systems.

Applied Materials said the partnership builds on decades of cooperation with Intel and is intended to address increasingly complex chipmaking challenges as AI workloads demand greater performance and efficiency.

Intel, meanwhile, said the collaboration will support its foundry ambitions by helping accelerate R&D and manufacturing innovation for advanced AI infrastructure.

Applied’s EPIC Center is expected to become operational in 2026 and is designed to give chipmakers earlier access to new equipment and process technologies, with the aim of bringing semiconductor breakthroughs to market faster.

💬 🔗

The Investor 10-06-26

Intel Foundry and ASML Advance High NA EUV for Next-Generation Chip Manufacturing

Intel (NASDAQ: INTC) and ASML are expanding their collaboration to accelerate industry adoption of High Numerical Aperture Extreme Ultraviolet lithography, a key manufacturing technology for increasingly advanced semiconductor designs.

Intel Foundry said High NA EUV is already being used in high-volume manufacturing, with more than one million wafers processed across equipment certification, R&D and production. The technology is being used on select layers of some Intel Core Ultra Series 3 processors, code-named Panther Lake.

Intel also said products manufactured on its Intel 18A process using High NA on selected layers are delivering performance that meets or exceeds comparable layers produced using conventional 0.33 NA EUV systems.

High NA EUV is designed to enable semiconductor manufacturers to print smaller and more complex chip features, making the technology increasingly important as AI and high-performance computing drive demand for more advanced processors.

Intel Foundry and ASML are also working to simplify adoption. Customers can currently use standard 6-inch masks through design optimization or Intel’s reticle-stitching technology, while the companies are collaborating with the broader semiconductor ecosystem on a future transition to larger 6x12-inch masks.

The update strengthens Intel Foundry’s position as an early adopter of High NA EUV. Intel installed ASML’s first commercial High NA system in 2024 and has since moved the technology from testing toward volume production, potentially providing an important manufacturing capability as Intel seeks to expand its foundry business.

💬 🔗

The Investor 09-08-26

Intel Stock Surges 9.3% as Wall Street Turns Bullish With Multiple Upgrades

Intel (NASDAQ: INTC) shares jumped 9.3% Tuesday to around $104.75 as several Wall Street firms adopted more bullish ratings on the chipmaker.

UBS upgraded Intel from Neutral to Buy, while RBC Capital Markets initiated coverage with an Outperform rating. Citigroup also initiated the stock with a Buy rating.

Northland Securities became more bullish as well, moving Intel from Market Perform to Outperform and setting a $120 price target. Based on Intel’s $104.75 share price, that target implies roughly 15% additional upside.

The wave of positive analyst actions highlights improving sentiment around Intel as investors assess the company’s turnaround and its position in the rapidly expanding AI and semiconductor infrastructure markets.

Intel has been investing heavily in advanced manufacturing and its foundry business while competing for growing demand associated with AI data centers and next-generation computing. Progress in these areas could be critical to improving profitability and strengthening Intel’s competitive position.

Tuesday’s combination of upgrades and new bullish coverage provided a strong catalyst for the stock, helping Intel shares climb more than 9% during the session.

💬 🔗

The Investor 09-08-26

Intel Stock Drops 3.7% After $15 Billion Share Offering Raises Dilution Concerns

Intel (NASDAQ: INTC) shares fell about 3.7% Monday after the chipmaker announced plans for a $15 billion underwritten public offering of common stock, as investors reacted to the potential dilution from the large equity raise.

Intel said proceeds from the offering will be used for general corporate purposes, including capital expenditures and working capital. The company said the additional capital will help it pursue opportunities related to AI computing, advanced packaging, purpose-built silicon and external wafer manufacturing while maintaining a strong balance sheet and investment-grade credit rating.

Offering Could Reach $17.25 Billion

The size of the capital raise appears to be the primary factor behind Monday's decline.

Intel plans to sell $15 billion of common stock and will give underwriters a 30-day option to purchase up to an additional $2.25 billion. If fully exercised, the transaction could therefore raise as much as $17.25 billion before fees and expenses.

Issuing such a substantial amount of new equity increases Intel's financial flexibility but dilutes the ownership and potential future earnings attributable to existing shareholders. The eventual dilution will depend on the offering price and number of shares issued.

Intel Points to AI and Foundry Investment Opportunities

Intel framed the offering as growth-oriented rather than defensive, saying customers continue to indicate strong and sustainable demand driven by unprecedented investment in AI computing.

The company highlighted physical AI, purpose-built silicon, advanced packaging and external wafer production as areas offering significant growth potential.

The capital could be particularly important as Intel continues investing heavily in semiconductor manufacturing infrastructure while attempting to expand its foundry business and compete in an AI semiconductor market dominated by companies such as Nvidia and increasingly contested by AMD and other specialized chipmakers.

Why Is INTC Stock Down Today?

Intel's roughly 3.7% decline appears primarily tied to dilution concerns surrounding the $15 billion stock offering.

While the transaction strengthens Intel's liquidity and gives the company additional resources to fund capital-intensive manufacturing and AI initiatives, existing shareholders effectively face a larger future share count.

The announcement also signals that Intel intends to continue committing substantial capital to its manufacturing and technology roadmap. Those investments could generate significant returns if AI and foundry demand develops as expected, but they also require considerable funding before their financial benefits become clear.

For now, investors appear to be focusing on the immediate dilution from one of Intel's largest equity raises, outweighing the longer-term potential benefits of additional investment in AI, advanced packaging and semiconductor manufacturing.

💬 🔗

European Investor 08-10-26

Intel (NASDAQ: INTC) edged 0.9% higher after Goldman Sachs upgraded its rating to Neutral from Sell, signaling a more balanced outlook on the chipmaker as it continues its turnaround efforts.

The rating change suggests Goldman sees a more favorable risk-reward profile following Intel's recent restructuring initiatives and progress in stabilizing its business. While the firm remains cautious about the company's competitive position and execution risks, the move away from a Sell rating indicates expectations for further downside have moderated.

Intel continues to invest heavily in expanding its manufacturing capabilities and advancing its foundry strategy, while working to regain competitiveness in the AI and data center markets. Investors are closely monitoring whether these long-term investments can translate into sustainable earnings growth.

💬 🔗

European Investor 06-25-26

Intel Surges 9% Premarket as Apple Foundry Reports and Analyst Support Boost Sentiment

Intel (NASDAQ: INTC) jumped 9% in premarket trading as investors reacted to news of a potential chip-manufacturing partnership with Apple and growing optimism surrounding the company's foundry and AI businesses.

Adding to the positive sentiment, Bernstein analyst Stacy Rasgon reiterated a Market Perform rating on the stock. While the analyst maintained a neutral stance, investors continue to focus on Intel's long-term turnaround strategy and efforts to become a major contract chip manufacturer.

President Donald Trump stated that Apple had agreed to work with Intel to design and manufacture certain chips in the United States (Stocktwits). While details remain limited and the companies have not provided comprehensive information about the reported arrangement, investors viewed the development as a potential validation of Intel's foundry strategy.

The broader semiconductor sector has remained one of the market's strongest performers in 2026, fueled by accelerating AI infrastructure spending and growing demand for advanced chips. Recent analyst upgrades and higher price targets across the industry have reinforced expectations that AI-related investment remains in the early stages of a multi-year expansion cycle.

For Intel, investor attention remains focused on execution of its manufacturing roadmap, foundry customer wins, and continued progress in AI and data-center markets. A successful expansion of its foundry business could diversify revenue streams and significantly strengthen the company's competitive position.

💬 🔗

WS Investor 06-18-26

Intel Climbs 5% After Double Analyst Upgrade Sparks Optimism

Intel (NASDAQ: INTC) shares rose about 5% on Thursday after receiving two major Wall Street upgrades, signaling growing confidence in the chipmaker's turnaround strategy and long-term AI opportunities.

Citigroup upgraded Intel to Buy, while Bank of America raised its rating from Underperform to Buy and increased its price target from $96 to $135. The rare combination of bullish analyst actions helped fuel strong investor interest in the stock.

The upgrades suggest that analysts increasingly believe Intel's restructuring efforts, manufacturing investments, and product roadmap are beginning to improve the company's competitive position. Investors have been closely watching Intel's progress as it works to regain market share in key processor markets while expanding its foundry business.

Analysts also appear more optimistic about Intel's ability to participate in the artificial intelligence boom. While competitors have captured much of the recent AI-related enthusiasm, Intel has been investing heavily in AI-capable processors, accelerators, and advanced manufacturing technologies that could support future growth.

The positive ratings come as sentiment toward the semiconductor sector remains strong, driven by expectations of continued AI infrastructure spending and rising demand for advanced chips. For Intel, the upgrades represent a notable shift in Wall Street's outlook after several years of operational challenges and market-share losses.

Thursday's rally suggests investors are increasingly willing to bet that Intel's turnaround is gaining traction and that the company could benefit from the next phase of semiconductor and AI industry growth.

💬 🔗

European Investor 06-11-26

Intel reported first-quarter 2026 revenue of $13.6 billion, up 7% year-over-year, as demand for AI-related computing and silicon products continued to grow. The company posted a GAAP loss per share of $0.73, while non-GAAP EPS came in at $0.29, reflecting ongoing investments and restructuring.

Intel highlighted strong momentum in AI-driven demand, particularly for its CPUs and advanced packaging technologies, alongside multiple product launches and expanded partnerships with companies including Google and NVIDIA.

Looking ahead, Intel expects second-quarter revenue between $13.8 billion and $14.8 billion, with modest earnings growth, as it continues to scale production and meet rising demand for AI infrastructure.

Source: Business Wire

💬 🔗

The Investor 04-24-26

Intel and Google Expand Partnership to Advance AI Infrastructure

Intel and Google announced a multiyear collaboration to enhance next-generation AI and cloud infrastructure.

The partnership will deepen the use of Intel Xeon processors across Google Cloud while expanding co-development of custom infrastructure processing units (IPUs), designed to improve efficiency, performance, and scalability in AI systems.

The companies emphasized the growing importance of CPUs alongside accelerators in managing complex AI workloads, with IPUs helping offload networking, storage, and security tasks to optimize overall system performance.

The collaboration aims to build more efficient, flexible, and scalable infrastructure to support rising global demand for AI-driven applications and services.
Business Wire

💬 🔗

WS Investor 04-09-26

Load More

10-19-26WS News

10-13-26The Investor

10-07-26Global Finance News

10-02-26WS News

09-18-26European Investor

NYSE:ABTFollow

Track all markets on TradingView - Prices are not updated in real time

Abbott Launches Pivotal Trial for Cephea Mitral Valve Replacement System

Abbott (NYSE: ABT) has initiated the CROWN-MV pivotal trial evaluating its investigational Cephea Mitral Valve System, a minimally invasive transcatheter replacement therapy for patients with symptomatic mitral valve disease who are not candidates for surgery or transcatheter repair.

The global prospective study will enroll up to 585 patients across the U.S., Canada and Europe. It will evaluate patients with moderate-to-severe or severe mitral regurgitation, as well as mitral valve dysfunction associated with mitral annular calcification.

Cephea is delivered through a catheter inserted through a vein in the leg and guided to the heart, where a bioprosthetic valve is implanted inside the diseased mitral valve. The system is designed to expand Abbott’s existing mitral valve portfolio, which already includes MitraClip and the Tendyne transcatheter mitral valve replacement system.

The pivotal trial follows encouraging early clinical development. Abbott said 30-day results from an early feasibility study using its third-generation Cephea delivery system will be presented at the TCT 2026 scientific meeting, with data expected to address mitral regurgitation reduction and quality-of-life outcomes.

The trial represents an important regulatory and commercial development milestone for Abbott’s structural heart business. If successful, Cephea could broaden treatment options for high-risk patients with complex mitral valve anatomy who currently have limited alternatives.

Abbott also plans to present additional TCT 2026 data across several cardiovascular platforms, including Amulet 360, SonicForce, Encantor, Amplatzer Paraclose and Navitor, reinforcing the breadth of its structural heart and cardiovascular pipeline.

💬 🔗

Global Finance News 11-01-26

Abbott Launches Ensure Max Protein 3-in-1 Muscle Support With Protein, Creatine and HMB

Abbott (NYSE: ABT) launched Ensure Max Protein 3-in-1 Muscle Support, a new powdered nutrition product that combines protein, creatine monohydrate and HMB in a single daily serving.

Each serving provides 30 grams of high-quality protein, 5 grams of creatine monohydrate and 3 grams of calcium HMB. Abbott said the formula is designed to support muscle building, exercise recovery and muscle preservation, targeting consumers who would otherwise combine several separate supplements.

The product reflects a broader consumer shift toward strength, active aging and muscle health. Abbott noted that ingredients such as creatine are moving beyond traditional sports nutrition as more adults focus on maintaining strength and physical function over time.

Ensure Max Protein 3-in-1 Muscle Support is available in chocolate and vanilla flavors and is being sold through major U.S. retailers including Walmart and Amazon. The product comes in a 28-ounce powder format, with a suggested daily serving of two scoops.

Abbott said the formulation is also NSF Contents Certified, providing third-party verification around ingredient quality and label accuracy.

The launch expands Abbott’s nutrition portfolio into the growing mainstream muscle-health category, combining elements of traditional protein supplementation with creatine and HMB in a single product aimed at active adults.

💬 🔗

Global Finance News 10-07-26

Abbott (NYSE: ABT) said the U.S. Food and Drug Administration approved new capabilities for its CardioMEMS HF System, allowing patients to view pulmonary artery pressure readings and receive personalized treatment updates through the CardioGuide HF App.

The update gives U.S. CardioMEMS patients direct access to their pulmonary artery pressure trends on smartphones. Rising pressure can indicate worsening heart failure weeks before symptoms such as shortness of breath or swelling appear, giving clinicians an opportunity to adjust treatment earlier.

Abbott also received approval for Dynamic Treatment Plan, a feature that lets care teams send individualized medication adjustment instructions to patients through the app based on changes in pulmonary artery pressure.

The company said the new tools are designed to strengthen remote heart failure management by keeping patients and clinicians more closely connected between office visits.

Abbott plans to make the CardioGuide HF App and Dynamic Treatment Plan available later in 2026.

💬 🔗

Global Finance News 10-06-26

Abbott Launches SimpleScreen CRC Blood Test for Colorectal Cancer Screening

Abbott announced the U.S. commercial launch of SimpleScreen CRC, an FDA-approved blood-based colorectal cancer screening test for adults age 45 and older who are at average risk for the disease.

Developed and manufactured by Freenome and exclusively commercialized by Abbott, SimpleScreen CRC expands the company’s colorectal cancer screening portfolio alongside Cologuard Plus. The blood-based test is intended as an option for eligible patients who decline or do not complete preferred stool-based or visual screening methods.

SimpleScreen CRC uses circulating cell-free DNA in blood to detect signals associated with colorectal cancer. In the PREEMPT CRC validation study involving more than 48,000 adults, the test demonstrated 81.1% overall sensitivity for colorectal cancer, including 63.5% sensitivity for Stage I disease. It also showed 90.4% specificity for advanced colorectal neoplasia.

Abbott said the test is covered by Medicare, with no out-of-pocket costs for eligible patients with Medicare Part B. Patients can complete the blood draw through participating laboratories or mobile phlebotomy services.

The company is also extending its patient navigation infrastructure to SimpleScreen CRC, including blood-draw coordination, reminders, insurance assistance, bilingual support and follow-up services.

Abbott is positioning the launch as a way to expand colorectal cancer screening participation by offering an additional noninvasive option for patients who might otherwise remain unscreened.

💬 🔗

The Investor 09-30-26

Abbott Highlights Lower Mortality and Hospitalization Risk With Libre CGM in Type 2 Diabetes

Abbott reported new real-world data linking continuous glucose monitoring, including its Libre technology, with lower mortality and fewer cardiovascular complications among adults with Type 2 diabetes using basal insulin.

In a U.S. study of nearly 28,000 adults, CGM use was associated with a 45% lower risk of death at 12 months and a 36% lower risk at 24 months compared with non-users. Researchers also found fewer cardiovascular-related complications among CGM users.

A separate French observational study involving more than 253,000 people with Type 2 diabetes found that acute diabetes-event hospitalizations fell 47% among basal-insulin users after starting Libre. The reduction was 56% among people using multiple daily insulin injections and 81% among those using non-insulin therapies.

Abbott is also highlighting new FreeDM2 trial analyses showing that people using Libre 3 experienced improvements in time in range within the first 24 hours, with benefits sustained over time.

The company is also showcasing Libre Assist, an AI-powered feature that predicts how food choices may affect glucose levels and provides personalized meal guidance.

The findings strengthen Abbott’s case for broader CGM use beyond intensive insulin therapy, although the mortality results are observational and show association rather than proof of causation.

💬 🔗

European Investor 09-28-26

Abbott and Berry Street Partner to Expand Personalized Nutrition Support Using Lingo CGM

Abbott and Berry Street announced an exclusive partnership that combines Abbott’s Lingo continuous glucose monitor with virtual support from registered dietitians to help consumers make more personalized nutrition and lifestyle decisions.

Lingo is an over-the-counter CGM designed for adults who are not using insulin. It shows how factors such as food, exercise, sleep and stress affect glucose levels, while Berry Street dietitians will use that data to provide individualized nutrition guidance.

Through the partnership, users can access dietitians trained on Lingo and continuous glucose monitoring, receive recommendations based on their glucose patterns and meet virtually through one-on-one appointments. Berry Street is in-network with more than 1,250 health plans, and the company said 96% of clients pay no out-of-pocket cost, depending on their insurance coverage.

Berry Street users will also be able to purchase Lingo at a 15% discount on four-week plans, while dietitians can view patients’ glucose data to provide more targeted coaching.

The partnership expands Abbott’s push into consumer metabolic health by combining real-time biosensor data with human nutrition expertise, rather than positioning glucose tracking as a standalone wellness tool.

💬 🔗

The Investor 09-23-26

Abbott Expands Volt Pulsed Field Ablation System to Canada

Abbott (NYSE: ABT) announced the first commercial use of its Volt Pulsed Field Ablation System in Canada, marking an expansion of the company’s next-generation technology for treating atrial fibrillation. The first Canadian procedures were performed at McGill University Health Centre in Montreal.

Volt uses high-energy electrical pulses to target heart tissue responsible for abnormal rhythms. Its balloon-in-basket catheter is designed to improve tissue contact and deliver precise energy with fewer therapy applications, while integration with Abbott’s EnSite X platform provides 3D cardiac mapping and reduces catheter exchanges.

The system can also support conscious sedation instead of general anesthesia and is designed to reduce radiation exposure during procedures, potentially improving procedural efficiency and recovery.

Health Canada authorized Volt in April 2026 following clinical evidence including Abbott’s 392-patient VOLT-AF IDE study. The system is also approved and available in the U.S., Europe and Australia, expanding Abbott’s position in the growing cardiac electrophysiology and pulsed-field ablation market.

💬 🔗

The Investor 09-15-26

Abbott Reaches $385 Million Settlement With DOJ Over 2022 Infant Formula Recall

Abbott said it reached an agreement to resolve U.S. Department of Justice and related state claims stemming from the company’s manufacturing operations and 2022 recall of powdered infant formula from its Sturgis, Michigan facility.

Under the agreement, Abbott will pay a total of $385 million to resolve the claims. The company emphasized that the settlement does not constitute a finding of fault or liability and said the government had previously closed its criminal investigation into the matter.

Abbott also said no unopened, distributed infant formula involved in the matter ever tested positive for Cronobacter sakazakii. According to the company, FDA testing of unopened products from the homes of infants investigated during the recall was negative, while the CDC later concluded there was no definitive link between the Sturgis facility and the clinical cases under investigation.

The settlement provides greater legal clarity around a major issue that has followed Abbott since the 2022 recall, which disrupted U.S. infant-formula supplies and drew significant regulatory scrutiny. The $385 million payment represents a financial cost for Abbott, but resolving the litigation removes an important source of uncertainty surrounding its nutrition business.

💬 🔗

WS Investor 09-14-26

Abbott Wins FDA Approval for TactiFlex Duo Ablation Catheter to Treat Atrial Fibrillation

Abbott (NYSE: ABT) received U.S. Food and Drug Administration approval for its TactiFlex Duo Ablation Catheter, expanding the company’s portfolio of cardiac ablation technologies for treating atrial fibrillation.

TactiFlex Duo combines pulsed field ablation (PFA) and radiofrequency (RF) energy in a single catheter, allowing physicians to use either energy source or a combination of both when treating complex AFib cases. Abbott said the flexibility can help physicians tailor procedures to individual patients while minimizing the impact on surrounding healthy tissue.

The catheter also integrates with Abbott’s EnSite X EP System, which provides real-time three-dimensional mapping and feedback during procedures.

FDA approval was supported by results from Abbott’s FlexPulse IDE study. Data recently presented at the European Society of Cardiology Congress 2026 showed favorable safety and effectiveness outcomes in patients with paroxysmal AFib.

The approval strengthens Abbott’s position in the rapidly developing PFA market and follows other recent cardiac ablation approvals across the U.S., Europe, Asia and Latin America.

Abbott plans to begin initial U.S. procedures soon, followed by broader commercial adoption in the coming weeks. The launch adds another treatment option to Abbott’s electrophysiology portfolio as the company expands its presence in technologies used to diagnose, map and treat abnormal heart rhythms.

💬 🔗

The Investor 09-08-26

Abbott Reports Positive Phase 3-Style Clinical Data for TactiFlex Duo AFib Catheter

Abbott (NYSE: ABT) announced positive 12-month clinical results for its investigational TactiFlex Duo Ablation Catheter, a device designed to treat challenging cases of atrial fibrillation (AFib).

TactiFlex Duo combines pulsed field ablation (PFA) and radiofrequency (RF) energy in a single catheter, allowing physicians to select or combine ablation approaches depending on a patient’s needs. The technology works with Abbott’s EnSite X cardiac mapping system to provide real-time feedback during procedures.

In the FlexPulse Global IDE study, 92.6% of patients with paroxysmal AFib had no documented recurrence of AFib, atrial flutter or atrial tachycardia under standard-of-care monitoring. Under more rigorous protocol-driven monitoring, 77.4% remained free from documented recurrence.

The study also met its primary effectiveness endpoint, with 74.6% of patients remaining free from documented arrhythmias, medication changes or repeat procedures. Abbott reported a 98.3% safety rate with no major safety events.

The results are important for Abbott’s electrophysiology business as competition intensifies in the fast-growing PFA market. Combining PFA and traditional RF energy in one catheter could differentiate TactiFlex Duo by giving physicians greater flexibility when treating more complex arrhythmias.

The device received CE Mark in Europe earlier this year, while the FlexPulse IDE study is intended to support an application for U.S. FDA approval. The latest data were presented at the European Society of Cardiology Congress 2026 and published in EP Europace.

💬 🔗

The Investor 08-31-26

Load More

01-22-26WS News